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ABSTRACT 
 
Perlecan Domain V Induces VEGF Secretion in Brain Endothelial Cells Through α5β1 
Integrin Dependent Mechanism 
a Novel Insight in Brain Tissue Recovery Following Ischemia. 
 (December 2010) 
Douglas Nelson Clarke, B.S., Texas State University 
Co-Chairs of Advisory Committee: Dr. Gregory J. Bix 
  Dr. Sumana Datta 
 
Stroke is the leading cause of long term disability and the third leading cause of 
death in the United States. Perlecan plays a significant role in brain development by 
sequestering and delivering growth factors to developing neuronal precursor cells in a 
neurovascular niche. Previous results demonstrated that perlecan proteolysis results in 
the cleavage of perlecan’s most C-terminal domain five (DV) in the post-ischemic brain. 
As post-stroke angiogenesis is an important step in post-stroke brain repair, I focused 
on the mechanism of DV’s role in brain angiogenesis in vitro. 
I first demonstrated that DV significantly increased brain endothelial (BE) cell 
migration, proliferation and tube-like formation suggesting DV is a pro-angiogenic 
factor for BE cells. I next investigated VEGF secretion from BE cells in the presence of 
DV. DV significantly increased VEGF secretion into the cell media, which was both dose 
and time dependent. Using quantitative real-time PCR, DV induced a maximal nine-fold 
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increase in VEGF expression, compared to control, indicating DV is an upstream 
regulator of VEGF transcription. DV treated cells show an increase in phosphorylation 
of ERK-(1/2) that could be blocked by the pharmacological inhibitor U0126. This 
inhibitor could also block DV’s effect on VEGF mRNA expression and secretion 
indicating ERK is involved with DV’s effect on VEGF regulation. Optical sensor binding 
assays confirmed that DV binds to the α5β1 integrin with a Kd of 160nM, and cells 
treated with DV showed a visual representation of integrin α5β1-DV colocalization. 
Furthermore, shRNA-mediated knockdown of integrin α5 blocked DV’s effect on VEGF 
mRNA expression, indicating integrin α5 is involved with DV’s regulation of VEGF 
expression.  
In conclusion, these results demonstrate that DV has an unexpected pro-
angiogenic effect in brain angiogenesis. This occurs via a previously unreported 
interaction between DV and the α5β1 integrin, resulting in the activation of the ERK, 
eIF4A and HIF1α signaling pathway and an ultimate increase in VEGF mRNA expression 
and VEGF secretion. As DV is generated post-stroke, these results suggest a novel 
mechanism by which brain tissue recovery following ischemia is influenced by 
processed fragments from the extracellular matrix. 
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CHAPTER I 
INTRODUCTION 
Stroke, also referred to as a “brain attack”, is the leading cause of long term 
disability and the third leading cause of death in the United States.  Two types of stroke 
exist. Ischemic stroke is where there is loss of blood flow to a brain region due to a 
blood clot occluding a cerebral artery, and hemorrhagic stroke, where there is an 
excessive amount of blood released in the cranium due to the rupture of a blood 
vessel. Eighty seven percent of patients who are affected by neurovascular stroke 
suffer from ischemic stroke while the remaining population suffers from hemorrhagic 
stroke. Regardless of the type of stroke suffered, the brain attempts post-stroke repair. 
However, while incremental advances have been made in acute stroke treatment, 
understanding of the mechanisms underlying brain self-repair after stroke remains 
poor. Therefore, the problem of brain repair and stroke rehabilitation is an emerging 
research priority (Grotta et al., 2008), with the underlying goals of identifying and 
improving brain reparative process.  
In order to identify and foster brain reparative processes for better patient 
outcomes, the neurovascular unit must be appreciated. The neurovascular unit consists 
of several cell types within the brain including endothelial cells, astrocytes, pericytes 
and neurons, all of which are closely knit together by the extracellular matrix (ECM).  
 
    
This dissertation follows Journal of Cell Biology. 
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The ECM, in turn, plays many important roles in cell biology by regulating cell 
morphology, controlling cell fate, providing scaffolding, and regulating cell-to-cell 
interactions (Greenberg and Kunlin, 2005). 
Within the last two decades, research has focused on investigating the cryptic 
fragments that are released from the extracellular matrix when exposed to active 
proteases such as matrix metalloproteinases (MMPs) and cathepsins. During ischemia, 
there is an increased release of these proteases within the stroke ischemic core (central 
region of irreversible neuronal injury) and penumbra (area surrounding the ischemic 
core) that leads to proteolysis of the ECM. Processing of the ECM can lead to the 
generation of ECM fragments with potential effects on the surrounding neurovascular 
unit. Frequently, these fragments have been shown to be negative regulators of new 
blood vessel development from pre-existing vasculature (angiogenesis) among other 
neurovascular effects.  
Among several components of the ECM, perlecan, a heparan sulphate 
proteoglycan, has been shown to be a source for such a cryptic fragment, its C-most 
terminal domain, domain five (DV). Previous research has characterized this 82kDa 
fragment as a negative regulator of angiogenesis outside of the brain via interaction 
with the α2β1 integrin and inhibiting vascular endothelial growth factor (VEGF) activity 
(Nystrom et al., 2009). 
Although the anti-angiogenic capacities of these cryptic fragments have been 
exploited for therapies used in pathological diseases such as cancer, little research has 
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been performed investigating the roles of these cryptic fragments on the neurovascular 
unit following ischemic stroke. There is a basic understanding following ischemia that 
ECM proteolysis is induced, but underlying questions still remain unanswered: are 
cryptic ECM fragments generated after ischemic stroke? What happens if/when these 
cryptic fragments are released? Do they affect the surrounding vasculature and how?  
In this dissertation, I focus on the mechanism by which perlecan’s DV fragment 
unexpectedly induces brain angiogenesis in vitro. My research provides novel insight on 
the regulatory effects mediated by the ECM, particularly perlecan’s DV fragment, and a 
plausible mechanism describing brain tissue recovery following neurovascular stroke.  
 
Stroke 
It is estimated stroke will cost $73 billion in direct and indirect costs for health 
care during the year of 2010. Currently, more than six million people, greater than or 
equal to 20 years and older, in the United States have suffered from a stroke. More 
women than men will suffer from a stroke for two reasons: women tend to live longer 
than men and suffer from an imbalance of hormones incurred following menopause. 
The most common high-risk factors for both sexes in stroke are hypertension, smoking, 
diabetes mellitus and depression (Lloyd-Jones, 2010). 
Currently the only FDA approved drug for acute ischemic stroke treatment is 
tissue plasminogen activator (tPA). tPA is a clot busting agent suitable for patients who 
suffer from ischemic stroke or heart attack. The major down side to tPA is its limited 
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therapeutic window of three to four and a half hours following the onset of stroke 
symptoms. Unfortunately, many stroke patients do not recognize their stroke 
symptoms as such until it is too late for tPA administration, or worse are initially 
misdiagnosed in the emergency room putting them outside the window of opportunity 
for tPA (Lloyd-Jones, 2010).   
Two types of stroke exist: ischemic and hemorrhagic. An ischemic stroke can 
generally be defined as an event in which blood supply to the brain has been blocked, 
typically by a thrombus, leading to the depletion of sufficient oxygen and nutrients 
needed for cell survival. Patients who suffer from hemorrhagic stroke can either suffer 
from an intracerebral or subarachnoid hemorrhagic stroke. An intracerebral 
hemorrhage occures when there is bleeding within the brain, while a subarachnoid 
hemorrhage occurs when there is bleeding in the subarachnoid space. Eighty seven 
percent of patients who are affected by stroke suffer from ischemia, ten percent suffer 
from intracerebral hemorrhagic and the remaining three percent suffer from 
subarachnoid hemorrhage This dissertation will focus on the more common ischemic 
stroke.  
Immediately following an ischemic insult, an ischemic cascade takes place that 
can ultimately lead to apoptosis. The initial processes following ischemia are energy 
failure, loss of ion homeostasis, depolarization, and water influx (Siesjo, 2008). 
Apoptosis following ischemia is initiated by internal and external events. The “intrinsic 
pathway” occurs when there is a disruption in oxygen levels that leads to the disruption 
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of the mitochondria and subsequent release of caspases, following ATP-dependent ion 
transport failure. Once this happens, there is an influx of cytosolic calcium ions within 
the cell which leads to cell stress and the release of glutamate. The release of excess 
glutamate, the presumed prime suspect in ischemic core damage, stimulates N-methyl-
D-aspartate (NMDA) or D, L-α-amino-3-hydroxy-5-methyl-isoxazolpropionic acid 
(AMPA) receptors causing neighboring cells to uptake more intracellular calcium 
ultimately leading to cell death. Sadly, pharmacological studies blocking NMDA and 
AMPA receptors have not been entirely successful, leaving this model of ischemic 
damage open to further investigation.   
Dying cells can have negative paracrine effects on neighboring cells by releasing 
apoptotic factors such as toxins, cytokines, and proteases, thus activating the “extrinsic 
pathway” (Broughton, 2009). These apoptotic factors then interact with pro-apoptotic 
cell surface receptors to induce caspase signaling cascades and ultimately the direct 
induction of apoptosis. The newly released apoptotic factors and resulting 
inflammatory responses cause the ischemic core to continuously grow while also 
putting the ischemic penumbra at risk for necrosis. 
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The area of severe ischemia, where irreversible neuronal injury occurs, is 
defined as the ischemic core. The area surrounding the ischemic core, the ischemic 
penumbra, is also at risk for cell death yet viable several hours following ischemic 
injury, (Ginsberg, 1997) but not indefinitely (Figure 1.1). Following middle cerebral 
artery occlusion (MCAO in the mouse, the ischemic core has a cerebral blood flow at or 
below 20% of normal and is unable to reverse injury because of potassium steady-state 
elevations which cause anoxic depolarization (AD). AD is a sudden and profound 
depolarization of neurons and glia in cortical and subcortical gray matter (Jarvis, 2001), 
and ionic dyshomeostasis, which refers to a disruption of intercellular calcium levels. In 
contrast, the ischemic penumbra has a cerebral blood flow approximately 20% to 40% 
higher than normal. It is electrically silent but above ionic dyshomeostasis (Ginsberg, 
1997) leaving the cells in a quiescent but viable stage. Therefore, targeting the viable 
cells within the ischemic penumbra with neuroprotective therapies may potentially 
lead to the rescue of neuronal injury, cell death and promotion of brain repair.  
 
 
 
 Figure 1.1. Ischemic stroke schematic.
cerebral blood vessel clot occlusion, i.e. an ischemic stroke. The core is defined as the 
area surrounding the blood vesse
occurs. The ischemic penumbra/peri
for cell death yet is still viable several hours following ischemic injury, thus allowing for 
neuroprotective therapies to rescue neuronal injury and cell death. Both areas are 
shaded in various colors of gray.
 
 This figure illustrates the consequence of a 
l distal to the clot where irreversible neuronal injury 
-infarct brain that surrounds the core is also at risk 
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Neurogenesis and angiogenesis are vital in brain repair not only to replace 
neurons that have rapidly degenerated post stroke, some as soon as one day following 
stroke (Hayashi et al., 2003), but also to help in reperfusion of blood supply and 
nutrients that are vital for cell survival. Yet the regulation of neurogenesis and 
angiogenesis following ischemia are not well understood. This lack of understanding 
leads to an underlying disconnect between the  bench and bedside for current stroke 
therapies and a critical need for identifying and improving brain reparative processes.  
Brain self-repair 
Brain recovery following ischemia involves the formation of new blood vessels 
(angiogenesis) and the re-population of neurons (neurogenesis). Indeed, following 
ischemia embryonic/developmental molecular signals are reactivated to regulate 
neurogenic and angiogenic processes for brain repair. Both of these processes occur in 
close proximity, i.e. in a neurovascular niche, (Ohab et al., 2006) (Krupinski et al., 1993) 
(Krupinski et al., 1994b) which affords mutually supportive growth factor-mediated 
neuron-endothelial cell cross-talk (Jones et al., 2001), (Stumm et al., 2002), (Guo et al., 
2008). In the neurovascular niche, diffusible growth factors help afford cross-talk 
between the closely associated brain endothelial cells and the neuronal precursor cells 
in a fashion that is consistent with the developmental association of neurogenesis and 
vasculogenesis (Wurmser et al., 2004).  
In order for proper neurogenesis to occur following ischemia, neural stems cells 
must proliferate, differentiate and migrate to the ischemic penumbra where they 
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mature to neurons and integrate into the parenchymal tissue (Guo et al., 2008). For 
post-stroke neurogenesis in mice and rats, neuronal progenitor cell proliferation is 
significantly enhanced in the subventricular zone (SVZ) and the hippocampal dentate 
gyrus (DG). This occurs as early as two to three days post-stroke and correlates with a 
specific expression pattern of cytokines, chemokines and vascular growth factor 
signaling (Guo et al., 2008). Cell proliferation continues but peaks after one to two 
weeks and returns to control levels by three to four weeks (Jin et al., 2001).  
Once generated, these newly formed neuronal progenitor cells continue on for 
approximately two to three weeks in the DG but only for a week in the SVZ (Dempsey 
et al., 2003). Instead, the SVZ neuronal progenitor cells largely migrate as far as the 
striatal stroke penumbral area and once there, differentiate into mature striatal 
neurons and astrocytes (Parent et al., 2002). Unfortunately, relatively few neural 
progenitors migrate into stroked tissue and those few that complete the trip usually fail 
to become mature neurons for unknown reasons (Jin et al., 2003).  
For angiogenesis in mice, endothelial cell proliferation can occur as early as 12 
to 24 hours post middle-cerebral artery occlusion in the ischemic middle cerebral artery 
territory (Hayashi et al., 2003). These newly generated endothelial cells then migrate 
towards the ischemic penumbra in response to a number of endothelial cell 
chemoattractants such as vascular endothelial cell growth factor (VEGF) and platelet 
derived growth factor (PDGF). The endothelial cells then form new blood vessels in 
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peri-infarct cortex after three to seven days, (Hayashi et al., 2003) with angiogenesis 
continuing for at least 21 days after.  
In addition to providing nutritive blood flow to the surrounding tissues, 
previously and newly formed angiogenic blood vessels are beneficial following ischemia 
because they serve many roles in brain repair. As noted earlier, neuronal migration is a 
key step towards proper brain repair. In order to help neuronal migration, newly 
formed angiogenic blood vessels can serve as physical scaffolds or “railroad tracks” for 
new neurons to migrate toward the ischemic core, even in the absence of blood flow 
(Ohab et al., 2006). Ohab et al. (Ohab et al., 2006), have demonstrated the importance 
of close physical associations between neuroblasts and endothelial cells in order to 
help neuroblast survive and get to areas, such as the ischemic penumbra, of vascular 
remolding following stroke.  
The newly produced vasculature also helps promote neurogenesis and 
neuroblast migration by the secretion of growth factors that influence the biological 
activity of neuroblasts. Angiopoietin 1 (Ang1) and stromal-derived factor 1 (SDF1) 
(Hohenstein et al., 2005), (van Weel et al., 2007) are endothelial secreted factors that 
act on the neuroblast Tie2 and CXCR4 receptors, respectively (Jones et al., 2001), 
(Stumm et al., 2002). Erythropoietin (EPO) also increases the number of immature 
neurons in the peri-infarct tissue (Zhang et al., 2005). Neuroprotection, neuronal 
migration, and neural stem cell renewal are also afforded by vascular production of 
brain-derived neurotrophic factor (BDNF) binding to neuronal TrkB receptors (Guo et 
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al., 2008), (Snapyan et al., 2009), (Li et al., 2006). However, this may not be the case in 
the adult mouse and rat subventricular zone (Galvao et al., 2008). A recently defined 
example of neurovascular cross-talk occurs in brain endothelial cell-neural stem cell co-
cultures. Neural stem cell Nitric Oxide (NO) reportedly induces brain endothelial cell 
release of BDNF and VEGF, which in turn induce endothelial cell angiogenesis via 
VEGFR2 and TrkB receptors. The release of BDNF and VEGF neuronal stem cell renewal 
effects (Li et al., 2006).  
In addition to VEGF, BDNF and EPO, several reports describe other important 
growth factors and their roles in neurovascular remodeling. For example, the 
expression of basic fibroblast growth factor 2 (FGF-2) has been shown to increase the 
migratory capacity and proliferation of neural progenitor cells (NPC) following 
transplantation into the neonatal ischemic cortex (Dayer et al., 2007). Furthermore, 
Teramoto et al (Teramoto et al., 2003) have demonstrated that epidermal growth 
factor (EGF) can be used to promote brain self-repair by increasing endogenous 
neuronal replacement following ischemia. Finally, Insulin-like growth factor I (IGF-1) has 
also shown promise in brain ischemic injury. Current evidence suggests that IGF-1 is 
neuroprotective, has the ability to cross the blood brain barrier, and when over  
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expressed following acute ischemic injury can improve motor performance in mice (Zhu 
et al., 2008).  Collectively, niche neurovascular coupling appears to represent an 
important means of post-stroke brain repair that could be therapeutically exploited 
(Arai et al., 2009).  
Angiogenesis and the extracellular matrix 
Blood vessels are composed of two interacting cell types, endothelial cells and 
perivascular cells. Endothelial cells line the inside of the vessel wall, while perivascular 
cells envelope the surface of the vascular tube (Bergers, 2005). Angiogenesis is the 
formation of new blood vessels from pre-existing blood vessels, including the 
remodeling of adult endothelial cells to arteries, veins and capillaries (Hayashi et al., 
2003), (Serini et al., 2006). Angiogenesis occurs in multiple steps: detachment of 
pericytes from the vascular tube, breakdown of the extracellular matrix (ECM), 
proliferation and migration of new endothelial cells, and finally tube morphogenesis 
(Figure 1.2). The onset of angiogenesis occurs as a response to a stimulus such as a 
growth factor or cytokine, or following an insult such as a wound. Following pro-
angiogenic stimuli, pericytes detach, allowing previously inhibited endothelial cell 
proteases to begin breaking down the ECM (Saunders et al., 2006). Once the ECM is 
broken down, endothelial cells begin to proliferate and migrate out towards new 
angiogenic stimuli. Following migration, endothelial cells form new tubes and release 
attractants for pericytes to once again come back and re-stabilize the vascular tube 
(Figure 1.2). 
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Figure 1.2. The angiogenic process. Once a pro-angiogenic stimulus has been sensed by 
endothelial cells, endothelial cells are activated and release pericytes for vascular tube 
destabilization. Following vascular tube destabilization, endothelial cells begin to 
proliferate and release proteases responsible for extracellular matrix degradation. The 
endothelial cells migrate out towards angiogenic stimuli and begin to remodel forming 
new tube vasculature. Once tube formation is complete, vascular stabilization is 
achieved once again by the recruitment of pericytes. Figure modified from The 
Angiogenesis Foundation, 2009. 
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 During embryonic development, the vascular system develops by 
vasculogenesis, the de novo production of blood vessels. Vascular development in the 
brain is different among species. For example, capillary sprouts migrating into the 
neuroectoderm from the perineural plexus begin at embryonic day 4.5 in the chick 
versus embryonic day 11.5 in the rat (Plate, 1999). For the rodent, vascularization in the 
brain lasts up to 2 weeks following birth, and then is dramatically down regulated to 
keep up with organ size (Plate, 1999). Once the primitive vascular system develops, 
angiogenesis initiates, and produces most of the blood vessels in the embryo, including 
those formed in the brain (Plate, 1999).  
Physiological angiogenesis is conditional in adult organisms, occurring only in 
processes such as the female menstruation cycle and pregnancy. But pathological 
angiogenesis, a process by which mature, adult blood vessels give rise to new blood 
vessels, is initiated in disorders such as cancer, wound healing, diabetic retinopathy and 
stroke. In mice, pathological angiogenesis can occur as soon as 12 hours post-middle 
cerebral artery occlusion (MCAO), and up to 21 days post-stroke in the ischemic 
penumbra (Hayashi et al., 2003). Once ischemia has taken place several events happen 
simultaneously. There are abrupt alterations in the ECM, changes in cell-surface 
integrin expression on several cell types such as neurons, astrocytes, and endothelial 
cells, and an increase in vascular permeability (del Zoppo and Milner, 2006).  All of 
these events are required for active angiogenesis to take place in the adult.  
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 The extracellular matrix 
The basement membrane is composed of several ECM proteins critical for 
important biological processes. It is formed by glycoprotein and proteoglycan 
protomers that assemble and form supramolecular infrastructures (Yurchenco and 
Schittny, 1990). The ECM has important roles in the control of vascular patterning, 
morphogenesis, neovessel stabilization, and the formation of organs (Bix et al., 2006), 
(Serini et al., 2006). One important process the ECM serves is as a substrate and 
scaffolding for migrating cells during development and the onset of pathogenesis in 
such cases as wound healing, tissue regeneration and repair (Abrahamson, 1986). A 
second function of the ECM is to form a protective barrier and common substrate for 
various cell types to keep them closely knit together. The ECM also is capable of 
regulating cell fate by activating cell surface receptors and triggering subsequent 
intercellular signaling cascades. The cerebral extracellular space constitutes roughly 
20% of the brain’s volume and consists of the proteins laminin-1, entactin/nidogen, 
Type IV collagen, fibronectin, and perlecan (Fukuda et al., 2004) (Kohling, 2006). 
Changes in the brain ECM after ischemia are poorly understood, but are potentially 
important because they can affect multiple cell types.   
The glycoprotein laminin-1 was first purified from engelbreth-holm-swarm (EHS) 
mouse tumor sarcoma cells (Orkin, 1977) (Paulsson et al., 1987). Laminin-1 structure is 
composed of three short-arm and one long arm glycoproteins linked together in a 
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fashion that resembles a crucifix. Alterations in laminin-1 during development can lead 
to several disorders such as blistering skin disease, epidermolysis bullosa, junctionalis 
and muscular dystrophy (Kohling, 2006). Laminin-1 contains the RGD amino acid 
sequence binding motif and other accessible interactive domains allowing it to easily 
bind integrins, heparan and other ECM components such as Type IV collagen and 
entactin/nidogen.  
Entactin/nidogen was first described as two separate entities when purified by 
Carlin (1981), but later were recognized to be the same macromolecule (Abrahamson, 
1986). The structure of nidogen is representative of a dumbbell, with large domains 
connected to one another by a linker and a rod. The domains of nidogens range from 
38 kDa to 85 kDa, the C-terminus domain being the largest. Two isoforms of nidogen 
exist, nidogen-1 and nidogen-2. Knockout of both nidogen-1 and nidogen-2 is 
embryonic lethal, yet knockout of just nidogen-1 or nidogen-2 is not, suggesting 
compensation and redundancy of function between the two isoforms. However, 
neurological defects such as limb weakness and seizure-like behavior occur when 
nidogen-1 alone is knocked out, indicating its importance in neurological development 
(Bader, 2005).  
During brain development, fibronectin and its receptor, α5β1 integrin, are highly 
expressed to promote a pro-angiogenic environment (Davis and Senger, 2008). 
Fibronectin’s positive effect on cell survival and proliferation is mediated through the 
α5β1 integrin (Milner and Campbell, 2002). Reports demonstrate that vasculogenesis 
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(the de novo production of blood vessels) and angiogenesis depend primarily on 
ibronectin and the α5β1 integrin (Serini et al., 2006) suggesting this integrin and ligand 
promote angiogenesis. Following development, maturation of the CNS no longer 
requires a pro-angiogenic environment but instead requires a quiescent environment. 
Therefore, there is a decrease in fibronectin and α5β1 integrin expression and an 
increase in α6β1 integrin and its ligand laminin type-1 which promote more of a 
quiescent environment (Milner et al., 2006). More recently, Milner et al. (2008) have 
demonstrated a pro-angiogenic “switch” following ischemia in which the vasculature 
reverts to a developmental, pro-angiogenic environment by increasing fibronectin and 
α5β1 integrin expression.  
Perlecan, (Figure 1.3), is involved with cell growth, proliferation, and brain 
development, (Bix and Iozzo, 2005).  This >400kDa heparan sulfate proteoglycan is 
divided into five distinct structural domains (DI-DV), and is encoded by a single gene, 
which is conserved among humans, Drosophila, C. elegans and mice Knox and 
Whitelock, 2006; Hassell et al., 2003; Bix and Iozzo, 2005; Noonan et al., 1991). Non-
lethal mutations in perlecan result in the Silverman-Hand maker type of dyssegmental 
dysplasia and Schwartz-Jampel syndrome (Arikawa-Hirasawa et al., 2001) that are 
characterized by lethal dwarfism and short stature, respectively.   
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Figure 1.3. Schematic of perlecan and DV. Perlecan is divided into five domains, DI-DV, 
DI located at the N-terminus and DV the C-terminus. DV is made up of 3 Laminin 
Globular repeats that are separated by two epidermal growth factor repeats. Figure 
modified from Bix and Iozzo, 2005.  
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Perlecan-null mutations lead to malformations in cardiac outflow track, intra-
pericardial hemorrhage, severe cephalic and cartilage abnormalities and ultimately 
death in mice, C. elegans and humans (Mongiat et al., 2003),(Bix et al., 2004), (Bix and 
Iozzo, 2005), (Noonan et al., 1991).  In mice, perlecan mutations cause developmental 
defects of the heart, brain, kidney and skeletal muscles (Farach-Carson, 2007).  The 
perlecan locus in C. elegans is referred to as UNC-52; mutations in UNC-52 are linked to 
body wall muscle defects and abnormal formation of integrin complexes (Rogalski et 
al., 1995).  The perlecan homologue in Drosophila, trol- (terribly reduced optic lobes), 
has a phenotype of small eyes and brains because of quiescent neuroblasts failing to 
initiate proliferation (Farach-Carson, 2007).  
Interestingly, perlecan can be synthesized and secreted by neurons, astrocytes, 
and endothelial cells (Shee et al., 1998), the latter induced by VEGF165 (Kaji et al., 2006). 
This suggests that multiple cell types are responsible for replenishing perlecan into the 
vascular basement membrane. Evidence indicates perlecan is the most protease 
sensitive and rapidly processed ECM protein following ischemia when compared to 
collagen or laminin after middle cerebral artery occlusion (MCAO), a commonly used 
animal model of ischemic stroke for rodents and non-human primates (Fukuda et al., 
2004). Perlecan proteolysis by the stroke-generated cysteine protease cathepsin L 
occurs within two hours of MCAO in non-human primates and persists for at least 
seven days (Fukuda et al., 2004). The sustained processing of perlecan for days after 
stroke is consistent with studies demonstrating an increase in perlecan production in 
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neurons and astrocytes after brain injury (Shee et al., 1998). The developmental, 
nonstroke neurovascular niche located in the subventricular zone, (Palmer et al., 2000) 
(Merecier et al., 2002) contains perlecan and its absence in mice results in severely 
impaired neurogenesis because of decreased capture of neurogenic factors (Kerever et 
al., 2007). As mentioned previously, one product of perlecan proteolysis is the domain 
V (DV) fragment, which has been shown to inhibit angiogenesis in human umbilical vein 
endothelial cells (HUVEC) in vitro and in vivo. Proteolysis of perlecan by cathepsin L 
leads to the cleavage of DV from perlecan (Cailhier et al., 2008), suggesting that 
following ischemia, DV could be released from perlecan by cathepsin L.  
Proteolytic processing of the extracellular matrix 
During a stroke, dying and infiltrating inflammatory cells release matrix 
metalloproteinases (MMPs) and cathepsins, which disturb the blood brain barrier and 
proteolytically process the ECM (Fukuda et al., 2004). The major players involved with 
ECM processing following brain ischemia are tissue plasminogen activator (tPA), the 
MMP family and the cathepsin family. The expression, activity, and roles of these 
proteases are actively being investigated to better define their importance following 
brain injury. MMPs, cathepsin-L and tPA expression are up regulated following stoke.  
Overproduction of MMPs can result in cell death and inflammation. Inhibitors of the 
MMPs have been shown to reduce edema and infarction size (Durukan and Tatlisumak, 
2007).   
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The initial processing and degradation of ECM is largely thought of as a negative 
consequence of acute stroke in that it increases blood-brain barrier permeability, but 
an additional consequence of matrix proteolysis is the generation of bioactive matrix 
fragments (Tian et al., 2007). Indeed, many matrix components are known to harbor 
bioactive matrix fragments in their C-terminal regions that can inhibit angiogenesis 
outside of the central nervous system (Mundel and Kalluri, 2007), (Bix and Iozzo, 2005), 
but their capability of affecting angiogenesis remains uncharacterized in the brain. 
Alterations in ECM can start as soon as two hours post-cerebral ischemia in the non-
human primate (Milner et al., 2008b). Roughly 60% of cerebral ECM proteins are lost in 
the ischemic core within 24-hours post MCAO (del Zoppo and Milner, 2006). These 
results suggest the probability of generating bioactive matrix fragments following 
ischemia is highly likely.  
Currently, the generation and role of biologically active ECM fragments in 
ischemic stroke is poorly understood. Most of these fragments have been isolated from 
the ECM of tumor microenvironment and have been shown to inhibit angiogenesis. At 
least nine ECM derived inhibitors of angiogenesis have been reported (Lo, 2007). 
Proteolysis of fibronectin can produce a fragment called anastellin (C-terminal) that has 
antimetastic activity (Yi and Ruoslahti, 2001), while collagen type IV proteolysis 
generates three anti-angiogenic fragments: arresten, canstatin and tumstatin, 
depending on the alpha chain composition (Mundel and Kalluri, 2007). Endostatin, the 
C-terminus of the heparan sulfate proteoglycan collagen type XVIII, is also anti-
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angiogenic (Lo, 2007). Importantly, these angiogenesis inhibitors have been 
characterized primarily, but not exclusively (Ohab et al., 2006), outside of the central 
nervous system.   
Arresten, derived from the C-terminus of the type IV collagen alpha1 chain, 
inhibits migration, tube formation of stimulated endothelial cells, and the positive 
proliferative effect of basic fibroblast growth factor (bFGF) stimulated endothelial cells 
(Mundel and Kalluri, 2007). The mechanism by which arresten induces its anti-
angiogenic effect is likely because of interaction with the α1β1 integrin and subsequent 
blockade of MAPK signaling (Colorado et al., 2000), (Sudhakar et al., 2005). The 
interaction and blockade has been shown to inhibit hypoxia inducible factor-1α (HIF-
1α), an upstream factor that stimulates transcription of VEGF (Durukan and Tatlisumak, 
2007). A mutation in arresten has been linked to patients suffering from intracerebral 
hemorrhaging (Vahedi et al., 2009). This link suggests arresten is present in the brain.  
Currently there is no evidence the collagen type IV alpha2 or alpha3, parent molecules 
of canstatin or tumstatin, respectively, are present in the brain.  
Endostatin, the C-terminal fragment of collagen type XXVIII, was the first anti-
angiogenic peptide used in clinical research performed by Judah Folkman in the late 
1990’s (1996-1997;92:65-82). Endostatin has been shown by Tian et al. to be rapidly 
upregulated following ischemic stroke with unknown consequence (Tian et al., 2007).  
The increase is maximal two hours post-stroke and gradually fades by 48 hours post-
stroke, the last recorded time point. More recently, we have demonstrated by post-
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stroke day seven in rats, endostatin is undetectable (Lee et al, submitted manuscript) 
suggesting that endostatin is created rapidly but transiently after stroke.  Importantly, 
the release of endostatin following ischemia could have positive results. Endostatin has 
been documented to play a role in stabilizing cell-to-cell and cell-matrix adhesions. This 
could potentially play an important role in stabilizing the blood brain barrier (BBB) and 
decrease its permeability following ischemia (Durukan and Tatlisumak, 2007).  
Perlecan Domain V: a cryptic regulator of endothelial angiogenesis 
 Perlecan’s C-terminal 703 amino acids comprise DV, also known as endorepellin, 
which is further sub-divided into three laminin-like globular repeats separated by two 
epidermal growth factor (EGF) repeats (Figure 1.3) (Noonan et al., 1991), (Murdoch et 
al., 1992), (Kallunki and Tryggvason, 1992).  Laminin-1 and EGF, two proteins that are 
involved with regulating cell growth, proliferation, and differentiation, contain 
structural homology with DV (Hamann, 1995), (Senger, 2002).  Each EGF repeat 
contains 40 amino acids, with six conserved cysteines and conserved glycines for proper 
folding (Murdoch et al., 1992), (Kallunki and Tryggvason, 1992).  DV has multiple 
binding partners, including endostatin, α-dystroglycan, progranulin and nidogen 
(Mongiat et al., 2003), (Bix and Iozzo, 2008), (Woodall et al., 2008).  These proteins also 
regulate endothelial cell angiogenesis and in some cases wound healing (Bix and Iozzo, 
2008).   
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Within the past eight years, extensive research on perlecan’s DV fragment has 
characterized its effect on human umbilical vein endothelial cells (HUVECs) and solid 
tumor endothelial cells. DV has been demonstrated to inhibit angiogenesis in vitro by 
blocking HUVEC migration, tube formation, and in vivo by inhibiting blood formation in 
matrigel plug assays, CAM assays and decreasing tumor angiogenesis in rodents 
(Mongiat et al., 2003), (Bix et al., 2006).  DV blocks angiogenesis in HUVECs by 
autocrine signaling. Specifically, DV binds to the I-domain (i.e., the ligand binding 
domain) of α2β1 integrin, causing an increase in cAMP levels, protein kinase A (PKA) and 
focal adhesion kinase (FAK) activation, and ultimately disassembly of actin stress fibers 
(Figure 1.4). More recently, DV’s mechanism of action for inhibiting angiogenesis has 
been further dissected (Nystrom et al., 2009). The work performed by Nystrom et al. 
demonstrates that DV causes an increase in tyrosine phosphatase SHP-1 activity, which 
leads to the dephosphorylation of growth factor receptor VEGFR2, the main receptor 
for vascular endothelial growth factor (VEGF).  
 
 
 
  
Figure 1.4 DV/ER mechanism for disassembly of actin stress fibers and focal 
adhesions on HUVEC. Model depicting the pathway by which DV interaction with the 
α2β1 integrin causes the activation of PKA, P
of this pathway leads to the disassembly of actin stress fibers and focal adhesions. 
 
 
 
-FAK, P-p38MAPK and P-Hsp27. Activation 
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Domain V and integrins: a different function for brain repair and possible binding 
partners  
One way in which cells interact with the ECM is via cell surface receptors known 
as integrins. Integrins are a major class of cell-surface receptors consisting of 
transmembrane, noncovalently linked αβ heterodimers (del Zoppo and Milner, 2006), 
(Milner and Campbell, 2002), (Mark and Davis, 2002).  They are important for cell 
adhesion, contractility, movement, and growth by physically linking the ECM with the 
cell cytoskeleton (del Zoppo and Milner, 2006), (Shi and Sottile, 2008), (Wang and 
Milner, 2006b).With respect to angiogenesis, the interaction between the ECM and 
integrins helps regulate the migration and proliferation of endothelial cells by altering 
the presentation or localization of integrins on the cell surface. Endothelial cell 
migration is key for post-stroke repair, as the newly produced networks of endothelial 
cells become scaffolds directing the way for the newly migrating neurons in the 
ischemic penumbra and ultimately the site of injury within the ischemic core.   
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During migration, integrins assist endothelial cells by first anchoring them to the ECM 
thereby allowing the cell to polarize and then push off towards any present attractant. 
ECM ligands binding to integrins influence proliferation by activating intercellular 
cascades that are responsible for inhibiting or promoting proliferation.  
  Currently 8 β and 14 α integrin subunits have been identified (Hynes, 2008).  
Both subunits contain a hydrophobic transmembrane segment, a cytoplasmic domain 
containing 50 or less amino acids and an extracellular domain that is  greater than 75 
kDa for the β subunit and  greater than 100 kDa for the α subunit (Hynes, 2008). 
The first crystal structure of an integrin was the αVβ3, solved by Xiong et al. in 
2001 (Xiong, 2001).  Since then, it is believed that the integrin has different 
conformations: the bent conformation in which the integrin is resting and has low 
affinity for ligand, and the extended conformation, which is active and has high affinity 
for ligand. Activation of integrins was later referred to as the “switch blade model” 
(Figure 1.5).  
 
 
   
 Figure 1.5. Switchblade model for integrin activation. 
averages of αVβ3 conformational states.
affinity binding state for ligand. After a stimulus has taken place, the integrins are 
activated and are able to bind to ligand with high affinity. 
 
Electron microscopy image 
 Integrins are believed to be in a resting, low 
From Takagi et al
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 2002. 
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There are three classes of integrin α subunits: αIIb (which includes α5), α
M (which 
includes α2)
 and the third subunit, α4. These subunits contain a transmembrane domain 
and divalent cation repeats. Divalent cation repeats have been demonstrated to play a 
role in integrin activation. For example, the α5β1 integrin is activated by Mg
2+ and Mn2+, 
while Ca2+ will inhibit activation (Mould, 1998).  The αM subunit is distinguished from 
the other α subunits because it contains an I-domain, a 200 amino acid insertion in its 
N-terminus, which binds to collagens (Tuckwell et al., 1995) (Figure 1.6). 
There are three integrin receptors involved with angiogenesis in the brain that 
are re-expressed following ischemia and could be potential binding partners for DV: 
α5β1, α6β1 and αVβ3.  As mentioned previously, developmental angiogenesis in the 
brain is mediated by α5β1, which is the receptor for fibronectin.  Once the brain begins 
to mature, there is a switch in expression from the α5β1 integrin to the α6β1 integrin, 
the receptor for laminin, in order to maintain a quiescent environment (Milner and 
Campbell, 2002). Following an ischemic event, the brain goes back to a pro-angiogenic 
environment re-expressing fibronectin and the α5β1 integrin. 
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Figure 1.6.  Domains of αβ integrin subunits. The α β-propeller domain repeats are 
shaded in grey. Thigh and calf domains are represented in purple, green and light red. 
The β plexin-semaphorin-integrin domain is represented in dark grey, hybrid domains 
are represented in light blue and EGF domains are shown in black.  
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Directly following ischemic stroke, β1 expression in endothelial cells and 
astrocytes in the ischemic core is lost (del Zoppo and Milner, 2006), (Milner et al., 
2008b).  Transcription of β1 is increased in tissues surrounding the ischemic core and 
the ischemic penumbra (del Zoppo and Milner, 2006).  Integrin expression following 
ischemia can be recapitulated in vitro using the oxygen-glucose deprivation (OGD) 
model. OGD is a model used to recapitulate ischemia in vitro by limiting the availability 
of oxygen and glucose for cell survival. Endothelial cells that have undergone OGD 
increase the expression of α5β1 (Milner et al., 2008b) confirming that this model is 
consistent with in vivo studies.   
Hypoxia of the CNS in mice leads to high levels of α5β1 integrin and fibronectin 
from 0 to 14 days post-hypoxia, with its strongest level of expression at day 4 (Milner et 
al., 2008a).  The αVβ3 integrin is normally expressed on cerebral endothelial cells.  
Ischemia in mice and in non-human primates can stimulate early expression of αVβ3 
integrin within 1 hour (del Zoppo and Milner, 2006), (Lee, 2009). The αVβ3 integrin is 
not expressed on quiescent endothelial cells, but it is induced during angiogenesis 
where it can promote their proliferation and migration (del Zoppo and Milner, 2006), 
(Lee, 2009).  
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DV has previously been shown to inhibit angiogenesis in HUVECs and solid tumor 
endothelial cells via interaction with the α2β1 integrin.  Results demonstrate that anti-
angiogenic effects of DV in HUVECs do not occur in the absence of α2β1 integrin 
(Woodall et al., 2008).  In human and mouse microvessel brain endothelial cells there is 
no staining of α2 integrin (Rakic), (Wang and Milner, 2006b), (McGeer et al., 1990) and  
α2 null mice have no reported CNS abnormalities (Chen et al., 2002). Collectively, these 
results indicate the current receptor for DV is not present in the brain and suggests DV 
may play an opposite role in the brain because anti-angiogenic effects of DV do not 
occur in the absence of α2β1 integrin. However, DV may still play a role in angiogenesis 
following ischemia in the brain because DV has also been shown to block endothelial 
cell adhesion to fibronectin (Mongiat et al., 2003), suggesting that DV could potentially 
bind to the α5β1 integrin. As mentioned previously, following ischemia there is an 
integrin “switch” to promote a pro-angiogenic environment that includes the re-
expression of the α5β1 integrin. These data suggest a new receptor for DV that is 
present in the brain following ischemia.  
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Following MCAO in male baboons (Papio Anubis/cynocephalus), perlecan has 
been demonstrated to be the vascular matrix that is most sensitive component to 
proteolysis (Fukuda et al., 2004). Until now, no research has been performed 
investigating what fragments of perlecan are upregulated following ischemia. Research 
in our laboratory performed by Dr. Lee confirmed perlecan’s DV fragment is 
significantly upregulated in the stroked hemisphere of mice and rats (Figure1.7). 
Compared to contralateral hemispheres on post-surgery days 1, 3, 5, and 7, and 
corresponding contralateral hemisphere DV levels, DV in the stroked hemisphere was 
elevated at post-stroke day 1 (*p=0.0001), followed by slight diminishment at post-
stroke day 3 (**p=0.0007) and then further reduction to a plateau at post-stroke days 5 
and 7 (#p=0.007, ##p=0.005).  These results suggest that following ischemia, perlecan’s 
DV fragment can be generated from full length perlecan and thereby increase the 
amount of free DV around the cerebral vasculature. 
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Figure 1.7. Perlecan Domain V (DV) is transiently upregulated after stroke. (b) 
representative anti-DV western blot analysis with GAPDH loading control of the brains 
of rats, performed on post-stroke days 1, 3, 5, 7 on separated stroked and contralateral 
(non-stroked) cerebral hemispheres (brain from same animal on each post-stroke day). 
(c) Optical density analysis of DV western blot band intensities, mean (± standard 
deviation) values as normalized to corresponding GAPDH optical densities from n=5 
animals per each post-stroke date shown. DV was significantly elevated in the stroked 
cerebral hemisphere at all days measured (*p=0.0001, **p=0.0007, #p=0.007, 
##p=0.005 as compared to corresponding contralateral hemisphere levels).  
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Vascular endothelial growth factor 
 As described earlier, angiogenesis requires a multitude of steps in order for 
proper blood vessel development to occur. Within the vascular basement membrane, 
several growth factors exist which help support the surrounding vasculature during 
angiogenesis. Vascular endothelial growth factor (VEGF) was first identified for its 
vascular permeability function. Later it was recognized to be one of the most potent 
endothelial cell specific growth factors during angiogenesis (Ferrara, 2004).  VEGF was 
first purified and characterized as a permeability factor in 1983, where it was originally 
referred to as “tumor vascular permeability factor” (VPF). It wasn’t until years later that 
a different group unknowingly isolated the same protein but characterized it as having 
endothelial cell specific capabilities, naming it vascular endothelial growth factor, 
(VEGF) (Senger, 1983) (Senger, 1990). It was not until Connolly et al. sequenced VPF 
that it was confirmed that VEGF and VPF are the same molecule (Connolly, 1989). 
The VEGF molecule is a glycoprotein that forms a homodimer with a molecular 
weight of 46,000 daltons corresponding to the VEGF165 isoform (Ferrara, 1989). The 
VEGF gene is approximately 14 kilobases in size and consists of seven introns and eight 
exons (Houck, 1991) (Tischer, 1991) located on chromosome 6p21.3 (Vincenti, 1996).  
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Splicing of the VEGF gene generates six isoforms correlating to polypeptides that are 
121, 145, 165, 183, 189, and 206 amino acids long. The functionality of these isoforms 
is dependent upon where the splicing occurs. For example, isoforms 189 and 206 are 
cell associated and act as permeability factors because they contain heparin binding 
domains and are more basic in charge. VEGF 121 and 165 are both secreted, but 121 is 
weakly acidic and does not contain exons six and seven, which contain heparin binding 
domains, and it is therefore freely diffusible (Neufeld, 1996; Park, 1993) .   
Each member of the VEGF family utilizes three receptor tyrosine kinases, 
VEGFR-1/Flt-1, VEGFR-2/Flk-1, and Flt-4 in order to induce their angiogenic signals 
(Figure 1.8). VEGFR-1 and VEGFR-2 are linked to angiogenic responses while VEGFR-3 is 
also linked to lymphangiogenesis. Under physiological conditions, VEGF promotes 
endothelial cell proliferation and migration. During development this is detrimental as 
the vasculature matures. Following development, postnatal angiogenesis only occurs 
conditionally, during wound healing and the ovulatory cycle.  
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Figure 1.8. Schematic representation of VEGF receptors.  VEGF-R1 binds PIGF, VEGF-B 
and VEGF-A. VEGF-R2 binds to VEGF-A, VEGF-C, VEGF-D, and VEGF-E. VEGF-R3 binds 
VEGF-C and VEGF-D.  
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Several growth factors have been isolated and characterized as having effects 
on angiogenesis. Of these, VEGF stood out via its secretion capabilities and in knock out 
studies where absence of VEGF proved to be embryonic lethal. Since then, VEGF 
activity has been identified in several angiogenic in vitro models such as endothelial cell 
invasion into collagen gels, proliferation, induction of capillary-like structures and 
endothelial cell sprouting (Zachary, 2001). Other studies demonstrated VEGF 
capabilities in vivo using the chick chorioallantoic membrane (CAM) assay and rabbit 
cornea assay (Zachary, 2001). These studies prove that VEGF is capable of strongly 
promoting angiogenesis in vivo as well. 
Expression of VEGF is tightly regulated, yet several factors can influence 
initiation or inhibition of VEGF expression at the mRNA and protein levels. VEGF 
expression is up-regulated by activation of several receptors including tyrosine kinase, 
IGF and the FGF receptors (Tuder, 1995). Activation of these receptors can lead to the 
subsequent phosphorylation of extracellular-signal-regulated kinase (ERK) and 
phosphatidylinositol 3-kinase (PI3-kinase) / AKT signal transduction pathways, which in 
turn up-regulate VEGF expression (Berra et al., 2000), (Berra, 2000).  
p42/p44 MAP kinase cascade and hypoxia inducible factor 1-α (HIF-1α) are both 
up-stream regulators of VEGF expression. Under normoxic conditions, mitogen-
activated protein kinases (MAPK) are activated through a series of three 
serine/threonine specific kinase enzymes, MAPKKK, MAPKK, and MAPK. Extracellular 
signal-regulated kinases (ERK) p44/p42 kinase isoforms are implicated in several cellular 
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functions including control of protein synthesis, cell growth and cell survival (Berra, 
2000). Currently, there are two commercially available inhibitors selective for p44/p42 
kinases, 2´-amino-3´-methoxyflavone (PD98059) and 1, 4-diamino-2, 3-dicyano-1, 4-bis 
[2-aminophenylthio] butadiene (U0126), both of which bind to and inhibit ERK1/2 
function.   
VEGF is also under tight regulation by oxygen homeostasis. Regulation of oxygen 
homeostasis involves hypoxia-inducible factor 1 (HIF-1). HIF-1 is a herterodimeric 
protein consisting of a constitutively expressed HIF-1β subunit and an oxygen regulated 
HIF1-α subunit. Under normoxic conditions, HIF-1α is hydroxylated on proline residues 
402 and/or 564 by prolyl hydroxylase domain (PHD) proteins. Following prolyl 
hydroxylation, von Hippel-Lindau protein (VHL) binds to the hydroxylated HIF-1α 
facilitating ubiquitination of HIF-1α (Semenza, 2008). Under hypoxic conditions, HIF-1α 
is no longer hydroxylated which prevents it from being ubiquitinated by VHL. This 
allows HIF-1α to form a heterodimer with HIF-1β and subsequently bind to the hypoxia 
response element (HRE) located -975/-968 on the VEGF promoter (Forsythe et al., 
1996). Interestingly enough, work performed by the Pouyssegur group demonstrated 
that HIF-1 is a target for MAPK phosphorylation, and such an event also allows the 
induction of VEGF expression under normoxic conditions (Berra, 2000) (Figure 1.9).  
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Figure 1.9. VEGF expression regulation. Schematic representing the influence of 
hypoxia and activation of the p42/p44 MAPK pathway by growth factors have on 
increasing VEGF expression. Stabilization of HIF-1α allows it to form a complex with HIF-
1β where it binds to HRE located on the VEGF promoter and initiates transcription of 
VEGF.  
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Most research has focused on regulation of VEGF by its traditional receptors, 
VEGFR-1, VEGFR-2 and VEGFR-3, but little research has been conducted investigating 
nontraditional receptors such as integrins for VEGF regulation. As stated previously, 
under pathological conditions, the ECM is compromised and leads to proteolysis and 
the generation of ECM fragments. These ECM fragments are then able to influence the 
fate of neurovascular niche components by inducing the secretion of growth factors 
such as VEGF from cerebral endothelial cells. The complexity of interactions between 
integrins, VEGF and ECM has been investigated in retinal pigmented epithelial cells 
(Mousa et al., 1999). Mousa et al. demonstrated that blocking α5β1 integrin leads to 
partial blockade of VEGF secretion induced by ECM fragments, suggesting VEGF 
secretion can be mediated by α5β1 integrin and that ECM influences VEGF expression.  
Research objectives 
Objective 1 
 Angiogenesis along with neurogenesis is a key step in brain repair following 
ischemia. Studies following middle cerebral artery occlusion in this laboratory have 
revealed a significant increase in perlecan’s DV fragment in brain lysate taken from the 
stroked hemisphere compared to brain lysate taken from contra-lateral hemisphere or 
sham surgery control brain tissue. This first confirmed that cleaved DV generation is 
increased following stroke and is potentially available to interact with the surrounding 
microvasculature. Because other previous results have demonstrated DV to be anti-
angiogenic on human umbilical vein endothelial cells (Mongiat et al., 2003), the first 
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objective of this research was to investigate the in vitro angiogenic effects perlecan’s 
DV fragment has on brain cerebral endothelial cells.  
Objective 2 
 Previous reports investigating DV in vitro revealed DV interacts with the I-
domain of the α2β1 integrin (Bix et al., 2004). Furthermore, previous studies also 
demonstrate that the anti-angiogenic effects of DV in HUVEC do not occur in the 
absence of α2β1 integrin (Woodall et al., 2008).  In microvessel brain endothelial cells 
there is no staining of α2 integrin (Rakic), (Wang and Milner, 2006b), (McGeer et al., 
1990).  Moreover, α2 null mice have normal brain development and function (Chen et 
al., 2002). DV has also been shown to block endothelial cell adhesion to fibronectin 
(Mongiat et al., 2003) which suggests DV can bind to different receptors other than the 
previously reported α2β1 integrin. The second objective of this research was to identify 
a new receptor present in microvessel brain endothelial cells required for DV’s effect 
on in vitro angiogenesis.  
Objective 3 
 Endothelial cells are known to modulate neurogenesis partly because of the 
secretion of soluble growth factors such as VEGF, NGF and BDNF. In the neurovascular 
niche, these diffusible growth factors help provide cross-talk between the closely 
associated brain endothelial cells and the neuronal precursor cells in a fashion that is 
consistent with the developmental association of neurogenesis and vasculogenesis 
(Wurmser et al., 2004). DV has previously been reported to activate tyrosine 
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phosphatase SHP-1 (Nystrom et al., 2009), which causes a widespread reduction of 
growth factor receptor phosphorylation and subsequent blockade of angiogenesis in 
vitro. The third objective of this research was to investigate the regulation of VEGF by 
DV in  brain endothelial cells as a model for understanding the mechanism of DV 
mediated angiogenesis.  
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CHAPTER II 
PERLECAN DV INDUCES A PRO-ANGIOGENIC EFFECT ON BRAIN MICROVASCULAR 
ENDOTHELIAL CELLS IN VITRO 
 
Introduction 
 
Among Americans, stroke occurs on average every 40 seconds and kills one 
person every four minutes. Currently, there is no therapeutic cure for stroke patients, 
but advances in the stroke therapy field have left researchers with a sense of optimism. 
Following ischemia, the affected brain area was once thought to be an irreversible site 
of injury, yet recent developments suggest this may not entirely be the case. Since 
Santiago Ramon’s statement regarding adult neurogenesis, “everything may die, 
nothing may be regenerated,” researchers have proven not only does neurogenesis 
take place following ischemia, but traumatic injuries such as ischemia can stimulate 
brain neurogenesis (Colucci-D' Amato, 2006). For complete and proper functional 
recovery following ischemia, neurogenesis must be coupled with angiogenesis. The 
induction of angiogenesis following ischemia has been proven beneficial, serving as a 
means of replenishing oxygen levels and nutrients to affected tissue but also to 
promote neurorepair processes such as neurogenesis and synaptogenesis.  
 Following development, angiogenesis no longer exists except during the female 
reproductive cycle. Under pathological conditions such as ischemia, angiogenesis 
commences in order to support processes such as wound healing. Given these two 
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separate scenarios, Hanahan and Folkman then postulated a “switch” governs the 
angiogenic process (Mahabeleshwar, 2008). When angiogenesis is required, pro-
angiogenic proteins turn the switch on, and when angiogenesis is not required, anti-
angiogenic proteins turn the switch off.  
The extracellular matrix (ECM), which surrounds the neurovascular unit, 
contains multiple pro/anti-angiogenic proteins involved with angiogenic regulation. The 
ECM is critical for endothelial cell proliferation, migration, morphogenesis, survival and 
blood vessel stabilization (Davis and Senger, 2005). All of these stages are required for 
angiogenesis. Proteases that are upregulated following ischemia can initiate or “switch 
on” angiogenesis by degrading the ECM. Degradation of the ECM, once thought of as a 
negative process, can be beneficial under circumstances such as promoting 
angiogenesis. Breakdown of the ECM allows endothelial cells to migrate into the 
surrounding vascular space and proliferate into blood vessels. Breakdown of the ECM 
can cause the release of growth factors and bioactive fragments that were once 
sequestered in the ECM. These growth factors and bioactive fragments are now 
available to help promote endothelial cell migration, proliferation and stabilization 
during vascular remodeling.  
ECM degradation is the primary step in initiating angiogenesis, but also causes 
the release of several proteolytic ECM fragments into the interstitial space surrounding 
the neurovascular unit. Research has lead to the discovery of ECM fragments such as 
endostatin, tumstatin and endorepellin. These fragments have been found to be 
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potentially beneficial for inhibiting angiogenesis during cancer (Bix and Iozzo, 2005). 
However, little research has been performed investigating these same ECM fragments 
and their role in regulating angiogenesis following ischemia in the brain. Accumulating 
research investigating the role of ECM components in the cerebral microvasculature 
following ischemia is setting the foundation for investigation of these ECM fragments 
following ischemia, (del Zoppo and Milner, 2006), (Takagi, 2002), (del Zoppo, 2008), 
(Milner et al., 2008a) opening up an entirely new and exciting field of research. 
The heparan sulfate proteoglycan perlecan has been shown to be the most 
sensitive neurovascular ECM component following ischemia within the ischemic core. 
Studies have demonstrated a decrease in perlecan immunoreactivity as early as one 
hour and a continuous decrease up to two hours following MCAO (Fukuda et al., 2004). 
Perlecan has also been shown to harbor a C-terminal anti-angiogenic fragment, called 
endorepellin or DV. Previous research has investigated the regulatory mechanism by 
which DV inhibits angiogenesis in vitro and in vivo (Bix et al., 2004) (Bix et al., 2006). DV 
has been demonstrated to inhibit angiogenesis in vitro by blocking HUVEC migration, 
tube formation and proliferation and in vivo by blocking tumor angiogenesis and blood 
vessel formation in CAM and matrigel plug assays. DV’s inhibitory effect on 
angiogenesis is due to interacting with the α2β1 integrin (Woodall et al., 2008). 
Interestingly, results demonstrate that anti-angiogenic effects of DV in HUVEC do not 
occur in the absence of α2β1 integrin (Woodall et al., 2008).   
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In microvessel brain endothelial cells there is no staining for the known DV 
receptor component α2 integrin (Rakic), (Wang and Milner, 2006b), (McGeer et al., 
1990).  Moreover, α2 null mice have no reported CNS abnormalities (Chen et al., 2002). 
Other data implies that there is an additional DV receptor, as DV can also block HUVEC 
adhesion to fibronectin (Mongiat et al., 2003). DV’s role in post ischemic angiogenesis 
has currently not been elucidated, yet following ischemia there is an up-regulation of 
proteases such as cathepsin-L which causes proteolysis of perlecan and release of DV 
(Fukuda et al., 2004), (Cailhier et al., 2008). Until now, no research has been performed 
investigating what fragments of perlecan are upregulated following ischemia. As 
mentioned previously, research in our laboratory confirmed perlecan’s DV fragment is 
significantly upregulated in the stroked hemisphere of mice and rats (Figure1.7). These 
observations suggest a potentially new role and new receptor for DV following ischemia 
in the brain.  
In this study, using three separate in vitro angiogenesis assays, I have identified 
DV as a pro-angiogenic stimulator in brain endothelial cells derived from mice. Our 
analysis demonstrates DV stimulates tube-like formation, proliferation and migration of 
brain endothelial cells suggesting DV can promote angiogenesis in the neurovascular 
environment following ischemia.  
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Materials and methods 
Cloning and oligonucleotides  
Genomic DNA was prepared by amplifying cDNA from HUVEC cDNA utilizing a 
GC-rich PCR system and dNTPack (Roche Applied Science, Indianapolis, IN). The human 
DV gene was amplified by PCR using forward and reverse oligonucleotides. Forward 
primers were designed with NHE1 restriction enzyme sites at the 5’ end, and reverse 
primers were designed with XhoI restriction sites and His6 tag at the 3’ end.  Following 
digestion, the gene was later ligated into pCepPu vector, kindly provided by Professor 
Maurizio Mongiat (Center for Cancer Research, Aviano Italy), between the Nhe1 and 
XhoI sites. DH5α cells were transformed with pCepPuDV, plated on LB+ amp plates and 
incubated at 37°C overnight. Colonies were selected and grown in 500mL of LB+ amp at 
37°C overnight. pCepPuDV DNA was purified using Qiagen plasmid maxi prep kit and 
the sequence was confirmed (Gene Technologies Laboratory Texas A&M University, 
College Station). A cell line containing pCepPuDV was constructed by transfecting 
pCepPuDV plasmid into 293 EBNA cells, kindly provided by Maurizio Mongiat, using 
Lipofectamine™ 2000 as per the supplier’s instructions (Invitrogen).  Forward and 
reverse primers used are listed as follows: 
NHEI DV Forward 5'-AGG CTA GCG ATC AAG ATC ACC TTC CGG C-3'  
XHOI HIS DV REVERSE 5'-AGC TCG AGC ATG ATG ATG ATG ATG ATG CGA GG-3'  
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Domain V protein expression and purification 
Transfected 293 EBNA cells containing pCepPuDV plasmid were transferred into 
a CelLine adhere 1000 bioreactor (Argos Technologies, Elgin, IL) and grown for seven 
days in complete media containing 10% FBS, 1x Antibiotic/Antimycotic, 1% G418 
Sulfate, and 0.05ug Puromycin. After seven days the complete media was removed, the 
cells were washed five times with CD293 media containing 4mM L-glutamine, 1x 
Antibiotic/Antimycotic, 1% G418 Sulfate, and 0.05ug Puromycin to remove any serum, 
and then fresh CD293 media was added to the cells. After an additional seven days, the 
cells were harvested by centrifugation at 5000 X g for 10 minutes at 37C. The media 
was collected and filtered using a 0.45μM syringe filter.  After filtration, protease 
inhibitors (Roche) were added to the media at one pill per 50 mL of media. 0.02% 
Triton X was added to the media and the pH was adjusted to 8.0. Two mL of Ni NTA 
Agarose Beads (Qiagen) were added to a Kontes FlexColumn (Fisher Scientific) and 
allowed to settle. Once the beads were settled, wash buffer A (125mM Na3PO4, 40mM 
NaCl, 20mM Imidazole pH 8.0) was added to the column in order to equilibrate the 
beads and provide proper packing of the beads. Once the column was ready, prepared 
media containing DV-His tagged protein was added to the column and allowed to flow 
through by gravity at one drop per 10 seconds. After the media had run through, the 
column was washed with 10mL of wash buffer A and collected. DV-His was eluted off 
the column by adding 10mL of elution buffer (125mM Na3PO4, 40mM NaCl, 350mM 
Imidazole, 10% glycerol pH 6.0) to the column. One mL fractions of eluted protein were 
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collected and stored at 4°C. Protein quantification was performed using a BCA kit 
(VWR) and fractions containing protein were pooled together and then dialyzed against 
1X PBS. Following dialysis, if necessary, the DV-His protein was concentrated to the 
desired concentration by incubating DV-His in polyethylene glycol (VWR). The resulting 
protein preparation was methanol precipitated, run on a SDS gel and stained with 
Brilliant Blue G-colloidal stain (Calbiochem). Purified DV-His protein exhibited a single 
band at 85kDa. Purified protein was aliquoted and stored at -80C.  
Cell culture 
Human brain micro-vascular endothelial cells were purchased from Lonza 
(Basel, Switzerland) and Cell Systems (Kirkland, WA), and passaged as per the supplier's 
instructions. Mouse  and rat brain micro vascular endothelial cells were kindly provided 
by Jane Welsh, Texas A&M University, and passaged as previously described (Sapatino 
et al.). Primary mouse dermal endothelial cells were purchased from Celprogen, Inc. 
(San Pedro, CA) and maintained initially as recommended by the manufacturer. After 
the second passage, cells were passaged to flasks pre-coated with 1mg/ml gelatin and 
fed with culture medium. Briefly, 500 ml M199 was supplemented with 15% FBS 
(Invitrogen), 200mg bovine hypothalamic extract, 50 mg heparin (Sigma-Aldrich), 5 ml 
antibiotics (Invitrogen) and 0.5ml gentamycin (Invitrogen). In all endothelial cells, the 
presence of endothelial cell markers von Willebrand Factor and VEGF receptor was 
confirmed via immunohistochemistry and western blot.  
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Proliferation assays 
 Mouse  brain endothelial cells were seeded in 96-well plates at a concentration 
of 4 x 103 cells per well in IMDM media (Invitrogen) supplemented with 10% FBS 
(Invitrogen) 1x Antibiotic/Antimycotic and incubated overnight at 37C and 5% CO2. 
Following overnight incubation, complete media was aspirated off and cells that 
underwent treatment were washed with plain IMDM media to remove residual all 
serum. Purified DV and 1% media was added back to each well to a final volume of 
100μL and incubated for an additional 24 hours at 37C and 5% CO2. After 24 hours, 
20μL of MTS (3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium), was added to each well and incubated for an additional 
two hours at 37C and 5% CO2. Cell proliferation was measured following the two hour 
incubation by reading the 96-well plate at 490nm using plate reader. Proliferation was 
normalized to untreated 1% condition for each experiment.  
α2integrin expression 
 
 Brain microvascular cells were transfected with a plasmid vector (pEGFP-N2, 
Clontech) containing a sequence encoding the α2-subunit integrin with a C-terminal 
RFP fusion protein (Texas A&M University Biomedical Engineering). Empty vector was 
used as a control. Cells were allowed to recover during 24hours in IMDM medium 
containing no antibiotics. Transfection efficiency was appreciated after 24hours using 
an inverted fluorescent microscope.  
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Migration assay 
Cell migration was assessed with a modified Boyden Chamber (NeuroProbe, 
Gaithersburg, MD) following the instructions of the manufacturer. In the top chamber,  
brain endothelial cells were added to each well at a concentration of 50 x 103 cells per 
well. In the bottom chamber, VEGF (20ng/mL) or purified DV was added to each well. A 
polycarbonate membrane (PVD-free 8 micron pore) was coated with type I collagen 
and fitted in between the top and bottom chamber. After the chamber was set up, it 
was placed at 37C and 5% CO2 and incubated for 6 to 8 hours. Following incubation, the 
polycarbonate membrane was scraped on the apex surface to remove any cells that did 
not actively migrate through the 8 micron pores in the membrane. Next the membrane 
was incubated in 0.1% crystal violet for one hour, rinsed 3 times with 1xPBS and cell 
number was counted using a microscope.  
Capillary tube-like formation assays  
Twenty four-well plates were incubated at -20⁰C overnight along with 200μL 
pipette tips. Matrigel (VWR) was thawed on ice and approximately 50μL was aliquoted 
to each pre-chilled well in the 24-well plate. Even coating of the matrigel was 
accomplished using a pre-chilled pasture pipette. During cell collection, the matrigel 
coated plate was placed at 37C and 5% CO2.  Brain endothelial cells were seeded to 
each well at a concentration of approximately 50 x 103 cells per well in IMDM 
supplemented with 1% FBS to a final volume of 350μL. Purified DV was added to each 
well at a desired concentration. Experiments were run for 12 to 18 hours at 37C and 5% 
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Co2. Following incubation, cells were fixed with 4% paraformaldehyde in 1x PBS. Tube 
formation was imaged and quantified as tube pixels/high power field, 10 areas per 
condition using Adobe Photoshop, CS.  
Immunofluorescence of Actin Stress Fibers 
 Brain endothelial cells plated on type I collagen were treated with DV for 10 
minutes followed by fixation with 4% paraformaldehyde (VWR). Immunocytochemistry 
was performed to stain for vinculin (Sigma-Aldrich) (a focal adhesion component and 
marker) and stained for F-actin with rhodamine conjugated phalloidin (VWR). Following 
staining, pictures were captured using a Zeiss spinning disk confocal microscope and 
Retiga EXi Fast 1394 CCD Camera.  
Results and discussion 
Domain V increases angiogenesis in vitro 
 The induction of angiogenesis following cerebral ischemia has been proven to 
be beneficial by replenishing oxygen levels and nutrients to affected tissue and also in 
promoting neurorepair processes such as neurogenesis and synaptogenesis. 
Endothelial cells migrate, proliferate and form new capillaries during angiogenesis in 
order to restore blood supply and nutrients and to help promote neurogenesis in the 
ischemic environment following stroke. Within the ischemic environment, the 
angiogenic process is greatly influenced by bioactive fragments and growth factors that 
are released from the ECM following proteolysis. C-terminal bioactive fragments 
derived from the ECM are currently being exploited as anti-angiogenic therapies for 
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diseases such as cancer (Rodrigues, 2010) (Bix et al., 2006) (Colorado et al., 2000). 
These studies are currently proving ECM fragments can be used as a means for 
regulating angiogenesis in diseased states. However, investigations of these fragments 
promoting angiogenesis in cases such as stroke are sparse, leaving an entirely new field 
of research open for investigation. Therefore, I sought to investigate one proven anti-
angiogenic bioactive fragment, Perlecan’s DV fragment, and monitor its effect on brain 
micro vascular endothelial cells migration, proliferation and tube morphogenesis. 
Because DV’s previously reported receptor for its anti-angiogenic effect is not 
present in brain micro-vascular endothelial cells, I expected to observe a different 
effect induced by DV on in vitro angiogenesis assays. In order to investigate DV’s effect 
on brain micro vascular angiogenesis in vitro, I used the (3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) assay, modified 
Boyden Chamber and matrigel assays to monitor proliferation, migration and capillary 
tube-like morphogenesis, respectively.  
 Proliferation is one of the first steps endothelial cells undergo once active 
angiogenesis is initiated. Studies evaluating cell cycle proliferation have incorporated 
several techniques such as BrdU or 3H-Thymidine incorporation or non radioactive 
assays such as MTS. MTS is reduced to formazan by dehydrogenase enzymes produced 
by metabolically active cells (Figure 2.1). An increase in the number of cells correlates 
to an overall increase in activity of mitochondrial dehydrogenases in the sample.  
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Figure 2.1. Structure of MTS and its soluble product formazan. Dehydrogenase 
enzymes that are present in metabolically active cells convert MTS to formazan. The 
amount of Formazan is directly proportional to the amount of proliferating cells and 
can be measured by reading its absorbance at 490nm. Modified from Promega, 2010. 
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The amount of soluble formazan detected at 490nm is directly proportional to the 
number of living cells in culture.  Brain endothelial cells grown in IMDM supplemented 
with 1% FBS media were used as the baseline control population. To control for DV’s 
previously reported anti-angiogenic effects, mouse dermal endothelial cells were also 
treated under the same conditions.  Dermal endothelial cells showed a significant 
inhibition of proliferation because of the presence of soluble DV. DV was able to inhibit 
dermal endothelial cell proliferation by 40% as compared to control cells grown in 
DMEM supplemented with 1% FBS (Figure 2.2). These results are consistent with the 
notion DV induces an anti-angiogenic response to dermal endothelial cells. 
Interestingly, quantification of  brain endothelial cells treated with soluble DV had the 
opposite effect of dermal endothelial cells. DV significantly enhanced  brain endothelial 
cell proliferation 40% when normalized to control  brain endothelial cell proliferation 
(Figure 2.2).  Because DV interacts with the α2 integrin to cause an anti-angiogenic 
effect on HUVEC and dermal endothelial cells (Bix et al., 2006) and brain endothelial 
cells do not express this integrin (Woodall et al., 2008), I next transfected  brain 
endothelial cells with α2 integrin plasmid. Our hypothesis was if the α2 integrin is 
expressed in  brain endothelial cells, an inhibitory effect induced by DV would be 
observed. Contrary to DV’s pro-proliferative effect on  WT brain endothelial cells, DV 
inhibited proliferation of  brain endothelial cells expressing α2β1 integrin. (Figure 2.2) 
This suggests that the absence of α2β1 integrin from brain microvascular endothelial 
cells is essential to DV's pro-angiogenic effects in the brain.   
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Figure 2.2. DV increases brain endothelial cell proliferation. Quantification of 
proliferation of dermal and brain endothelial cells ± the addition of the α2 integrin 
plasmid following  48 hours ± DV in IMDM supplemented with 1% FBS media as 
measured via MTS assay. Values shown (n=15, mean ± standard deviation normalized 
to control proliferation arbitrarily set to 100%) demonstrate significant inhibition of 
dermal endothelial cell proliferation (* p=0.00005) and brain endothelial cells 
expressing α2 integrin (**p=0.00009) and significant enhancement of brain endothelial 
cell proliferation (# p=0.002) after treatment with DV.  
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 Endothelial cell proliferation and migration seem to occur simultaneously. 
Newly formed endothelial cells respond to stimuli such as VEGF and migrate towards 
these stimuli. These newly migrated endothelial cells will later form contacts with other 
endothelial cells and mature into newly formed capillaries. As stated previously, the 
ECM is constantly being degraded during angiogenesis in order to make way for newly 
migrating endothelial cells and their capillary networks. A byproduct of this process is 
the generation of ECM bioactive fragments that are now available to act upon local 
endothelial cells. DV has previously been shown to inhibit endothelial cell migration 
(Mongiat et al., 2003). I hypothesized DV would promote brain endothelial cell 
migration because of our finding DV promotes proliferation of brain endothelial cells 
rather than inhibit it, because of the absence of α2 integrin. In order to asses this 
hypothesis, mouse  brain and dermal endothelial cell migration was tested in the 
presence and absence of soluble DV using a modified Boyden chamber migration assay 
model. DV stimulated  brain endothelial cell migration towards VEGF, with a 450% 
increase in migration compared to controls (Figure 2.3). Consistent with previous 
results (Mongiat et al., 2003), DV significantly inhibited dermal endothelial cell 
migration. These results suggest DV can act as a stimulus for migrating brain 
endothelial cells.  
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Figure 2.3. DV increases  brain endothelial cell migration. Quantification of migration 
of dermal and brain endothelial cells towards VEGF (20 ng/ml) in a modified Boyden 
chamber migration assay ± direct exposure to DV (mean normalized values for n=15 ± 
standard deviation plotted), as normalized to random migration across the membrane 
in the absence of VEGF. DV significantly inhibited dermal endothelial cell migration (* 
p=0.0008 as compared to VEGF alone) but significantly enhanced brain endothelial cell 
migration (n=15, # indicates significance, p=0.000001 for DV).  
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To investigate DV’s effect on brain endothelial cell tube-like morphogenesis, I 
stimulated brain endothelial cells with DV and plated them on matrigel. Matrigel is 
solubilized basement membrane isolated from Engelbreth-Holm-Swarm mouse 
sarcoma cells and composed of laminin, collagen type IV, heparan sulfate proteoglycans 
and nidogen. The composition of matrigel allows researchers to investigate tube-like 
formation in the presence or absence of angiogenic stimulators or inhibitors.  
Previously, DV has been shown to inhibit HUVEC tube-like formation (Mongiat 
et al., 2003). Because of our results showing DV has opposite effects on  brain 
endothelial cells than on HUEVECs, I hypothesized DV would increase tube-like 
formation of  brain endothelial cells on matrigel. Micrographs (Figure 2.4a) show  brain 
endothelial cells form tube-like structures in the presence of DV. I observed capillary 
tube-like formation within three hours of DV treatment where as control cells did not 
show visible capillary tube-like formation until six hours after being plated on matrigel.  
Dermal endothelial cells were also plated in the presence or absence of DV and showed 
an inhibition of capillary tube-like formation in the presence of DV consistent with that 
previously reported for HUEVECs (data not shown). These results suggest DV promotes 
tube like morphogenesis of brain endothelial cells. 
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Figure 2.4. DV stimulates  brain endothelial cell capillary tube-like formation. a) 
Micrographs of  brain endothelial cell tube-like formation production for control cells or 
cells treated with DV.  Bar in lower panel indicates 50 um. b) quantification of Matrigel 
capillary tube assays for mouse dermal and brain endothelial cells demonstrating 
significant enhancement of brain endothelial cell tube formation and inhibition of 
dermal endothelial cell tube formation (n=15, #p=0.0009, n=15, *p=0.001, as compared 
to corresponding control, HPF=high power field, error bars=standard deviation). Tube 
pixels per high power field for both in the presence or absence of DV were measured 
and quantified. 
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Finally, as DV has been shown to cause a collapse of the actin cytoskeleton as 
part of its anti-angiogenic mechanism (Bix et al., 2004); I next investigated if DV had any 
effect on the actin cytoskeleton of  brain endothelial cells.   brain endothelial cells 
seeded in eight well chamber slides were treated with DV for 10 minutes in IMDM 
media supplements with 1% FBS. Following fixation cells were stained in green for 
vinculin, a protein involved with linking integrins to the actin cytoskeleton and in red 
for filamentous actin (F-actin) the protein responsible for cell spreading and motility.  
As shown in Figure 2.5,  brain endothelial cells maintain prominent actin stress 
fibers when treated with DV. This result is consistent with  brain endothelial cells that 
were not treated with DV.  There is no collapse of the actin cytoskeleton which was 
previously reported in dermal endothelial cells (Bix et al., 2004). This result suggests 
that DV does not negatively affect the actin cytoskeleton of  brain endothelial cells. 
Previous results (Fig 2.3) demonstrated DV has a positive effect on cell motility.  
 
 
 
 
 
 
 
63 
 
Because endothelial cell motility involves constant collapse and reformation and 
polarization of actin it could be suggested that the same phenomenon should be 
observed in the staining of  brain endothelial cells. Yet, the cells observed in our 
migration model and the cells stained for f-actin are experiencing different conditions. 
The endothelial cells are being challenged to migrate where as in our f-actin staining 
experiments, the endothelial cells are in a subconfluent mono layer, and are not 
stimulated to migrate. Finally, the DV-induced collapse of the actin cytoskeleton 
previously observed in HUVEC  (Bix et al., 2004) was also assayed in non-motile  brain 
endothelial cells, further emphasizing the difference in DV function within and without 
the central nervous system. Collectively, these results demonstrate that DV surprisingly 
has pro-angiogenic effects on  brain endothelial cells. These results were directly 
compared to those on mouse dermal endothelial cells where DV has been previously 
shown to inhibit proliferation, migration and tube formation (Bix et al., 2004). 
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Figure 2.5. DV does not cause  brain endothelial cell actin collapse.  brain endothelial 
cells plated on type I collagen were treated with DV for 10 minutes followed by fixation 
with 4% paraformaldehyde. Immunocytochemistry was performed to stain for vinculin 
(a focal adhesion component and marker) and stained for F-actin with rhodamine 
conjugated phalloidin. Unlike in non-brain endothelial cells (Bix et al., 2004), prominent 
actin stress fibers were unchanged despite the presence of DV. Images are 
representative. Bar is 2 μm.  
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DV was capable of stimulating three separate assays involved with measuring 
angiogenesis in vitro: proliferation, migration and capillary tube-like morphogenesis. 
DV also had no effect on f-actin stabilization in non-migrating cells. These results also 
indicate that DV’s effects on brain endothelial cells are distinct and different from those 
observed on non-brain endothelial cells. All three aspects of angiogenesis I investigated 
in vitro follow separate mechanisms involving the regulation of different signaling 
pathways. These data suggest DV could modulate the onset of angiogenesis by 
increasing the proliferation and migration of endothelial cells and also during the 
maturation of tube morphogenesis.  
Figure 2.2 demonstrates DV is a positive regulator of cell cycle for  brain 
endothelial cells by increasing their proliferation. The technique used to monitor their 
proliferation is the quantitative, well known and validated proliferative assay, MTS 
assay, which monitors proliferation by assessing the metabolic activity of the cells being 
treated. The amount of soluble formazan detected at 490nm is directly proportional to 
the number of living cells in culture.  However, potential pitfalls to keep in mind while 
using this experiment are different conditions or chemical treatments can give different 
results that can increase or decrease the metabolic activity and the use of tetrazolium 
salts are generally cytotoxic. The variations arise under circumstances by which these 
chemicals or treatments change the activity of succinate dehydrogenase, the main 
enzyme involved with reducing MTS to formazan (Wang, 2010). My results indicate that 
brain endothelial cells treated with DV have significantly more soluble formazan than 
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brain endothelial cells not treated with DV. These results suggest DV increases the 
metabolic activity of brain endothelial cells and therefore implies DV increases brain 
endothelial cell proliferation. DV was still able to inhibit the proliferation of dermal 
endothelial cells suggesting a difference between the two cell lines used. As mentioned 
previously, brain endothelial cells do not have the α2 integrin, therefore when brain 
endothelial cells were made to express the α2 integrin, proliferation was able to be 
blocked, indicating DV has a higher affinity for this integrin and its presence will dictate 
what kind of an angiogenic effect DV may have. Alternative assays to confirm DV is a 
pro-proliferative agent would be BrdU incorporation or 3H-Thymidine incorporation. 
My results also beg the question as to how DV is promoting an increase in 
proliferation of  brain endothelial cells. One way to investigate how DV is affecting cell 
cycle is monitoring the activation of cyclin-dependent kinase enzymes (Cdk) by cyclins.  
When the concentration of cyclins increases, they form complexes with Cdk and in turn 
promote the phosphorylation of substrates responsible for cell cycle control. Currently 
four cyclins can be monitored to investigate cell cycle, Cyclin D for G1-phase, Cyclin E 
for S-phase, Cyclin A for G2-phase and Cyclin B for Mitoses. Therefore, in order to gain 
further insight into the mechanism DV stimulates cell division, experiments utilizing 
flow cytometry and staining for the different cyclins (D, E, A and B) involved with 
regulating cell cycle, could be conducted.   
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DV‘s ability to enhance  brain endothelial cell migration towards VEGF in the 
modified Boyden chamber assay suggests DV is a chemotaxis agent. Consistent with 
previous results reported, DV inhibited dermal endothelial cell migration to VEGF.  
Other experiments performed using DV as the chemoattractant (data not shown) alone 
suggest DV stimulates  migration by directly acting upon the cells. The stimulation 
would suggest two plausible mechanisms:  DV is acting as a chemoattractant and 
directly promoting the endothelial cells to migrate, or VEGF is the chemoattractant but 
is potentiated by DV.  In the latter case, DV could be up regulating VEGF receptors 
involved with migration and making the endothelial cells more sensitive and therefore 
more responsive to the stimulus VEGF provides.  
 Once endothelial cells have arrived at their final destination, the endothelial 
cells organize to form new capillary networks. This process requires the newly formed 
endothelial cells to align, connect to one another and morph into hollow lumens. The 
ECM is intimately involved during capillary morphogenesis by providing guidance cues 
or controlling intercellular signaling by interacting with cell surface receptors such as 
integrins (Davis, 2005). Figure 2.4 demonstrates how DV induces rather than inhibits 
tube-like formation of  brain endothelial cells. This observation was not only a surprise, 
but also interesting because of the increase in speed that the cells made tube-like 
structures compared to cells not treated with DV. Other matrix components such as 
collagen and fibronectin have been shown to promote endothelial cell formation of 
pre-capillary cords (Davis, 2005); antagonists to their receptors have blocked tumor 
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angiogenesis in vivo (Senger, 2002). It has already been demonstrated that DV could act 
as an antagonist to collagen’s receptor inhibiting tube like formation in HUVECs (Bix et 
al., 2004). Our observation of an increase in tube formation rather than inhibition, 
suggests DV is activating an integrin responsible for tube morphogenesis, which would 
then potentially stimulate intercellular signaling cascades that are also involved with 
tube morphogenesis.  
These results demonstrate DV has a completely opposite effect on HUVEC and 
brain endothelial cells. DV increased brain endothelial migration, tube formation and 
proliferation along with maintaining prominent actin stress fibers. These results may be 
because of differences in respective microenvironments, differences in expressed 
receptors, such as the presence or absence of α2β1 integrin, or differences in signal 
transduction components. Indeed, angiogenic differences between brain and nonbrain 
endothelial cells have been reported. For example, Wnt/β-catenin signaling is required 
for CNS, but not non-CNS angiogenesis (Daneman et al., 2009). Another example is 
platelet-derived sphingosine-1-phosphate (S1P). Normally S1P is pro-angiogenic yet is 
anti-angiogenic in brain endothelial cells because of their lack of MT1-MMP expression 
(Pilorget et al., 2005). Additionally, the type XVIII collagen-derived inhibitor of 
angiogenesis, Endostatin, promotes angiogenesis in immature endothelial cells derived 
from differentiated embryonic stem cells (Schmidt et al., 2004).  
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CHAPTER III 
THE α5β1 INTEGRIN IS REQUIRED FOR PERLECAN DV’S PRO-ANGIOGENIC EFFECTS ON 
BRAIN MICROVASCULAR ENDOTHELIAL CELLS IN VITRO 
 
Introduction 
 Cell surface receptors greatly influence cellular processes such as shape, 
mobility, and cycle.  Mechanistically, a ligand attaches to the binding site of the 
receptor and causes an “outside-in” signaling event that induces a cellular response 
involved with shape, mobility, proliferation, etcetera. Integrins are heterodimeric 
transmembrane receptors involved with cell-to-cell and cell-to-ECM interactions. 
Integrins have the ability to control cell fate by numerous methods such as linking the 
matrix with the cell cytoskeleton, transducing extracellular stimuli to intracellular 
signaling (outside-in signaling), and increasing the receptor specificity by cellular 
activity (inside-out signaling) (del Zoppo and Milner, 2006).  
Currently eight β and 14 α subunits of integrins have been identified (Laurens, 
2009). Of those integrins, few are involved with developmental and pathological 
angiogenesis. Perlecan’s DV fragment has previously been reported to negatively 
modulate angiogenesis by interacting with the α2β1 on HUVECs, and this integrin is not 
present on brain microvascular endothelial cells. Therefore, I decided to investigate 
other potential integrins that are involved with inducing post stroke angiogenesis in 
order to understand DV’s pro-angiogenic mechanism of action on  brain endothelial 
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cells. During wound repair, there is an up-regulation of pro-angiogenic integrins 
responsible for regulating cell adhesive, migratory properties and cell cycle. There are 
three integrin receptors involved with angiogenesis in the brain that could be potential 
binding partners for perlecan’s DV following MCAO: α5β1, α6β1 and αVβ3 (del Zoppo and 
Milner, 2006). Interestingly, change or loss in expression of these integrins also 
correlates to alterations in ECM ligands such as laminin-1, collagen type IV, fibronectin 
and perlecan (Hamann, 1995), (Fukuda et al., 2004) during cerebral ischemia in non-
human primates. These observations further emphasize the direct relationship 
between ECM fragments and integrins and how this relationship dictates cell fate 
following ischemia.  
Following ischemia, the αVβ3 and α5β1 angiogenic integrins are re-expressed in 
order to promote angiogenesis and wound repair (Li, 2010), (del Zoppo and Milner, 
2006). The exact roles αVβ3 and α5β1 play in post ischemic angiogenesis are still being 
defined. Current research suggests that the αVβ3 plays a non-essential role in 
vasculogenesis and angiogenesis (Li et al., 2010), (Lee, 2009). Studies performed by 
Reynolds and co-workers have demonstrated mice lacking β3 integrins have enhanced 
tumor growth and angiogenesis, (Reynolds, 2002). Bader and co-workers have 
demonstrated mice lacking αV integrin maintain proper vasculogenesis and 
angiogenesis (Bader, 1998). More recently, the role of αVβ3 integrin in ischemic cerebral 
angiogenesis has been investigated in mice subjected to hypoxia (Li, 2010). In this work, 
Li and co-workers demonstrate that although the αVβ3 integrin is strongly induced on 
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angiogenic brain endothelial cells in mice subject to hypoxia, knock out of β3 integrin in 
mice show no obvious defects in cerebral angiogenesis following hypoxia. In fact, 
following hypoxia β3 null mice have an up-regulation in α5 integrin and an increase in 
proliferating cerebral endothelial cells. These observations further suggest the 
importance of α5β1 integrin following ischemia and its role in the regulation of 
angiogenesis in the ischemic central nervous system. 
During development, cerebral capillaries express high levels of α5β1 integrin 
(Milner et al.). The importance of α5β1 integrin during development has been 
demonstrated in α5-null mice showing these mice have a phenotype of significant 
defects in blood vessel formation (Francis et al., 2002). Following maturation, there is a 
switch in expression from the α5β1 integrin to the α6β1 integrin, the receptor for 
laminin, in order to maintain a quiescent environment (Milner and Campbell, 2002). 
Directly following ischemic stroke in non-human primates, β1 expression in endothelial 
cells and astrocytes in the ischemic core is lost (del Zoppo and Milner, 2006), (Milner et 
al., 2008b).  Transcription of β1 is increased in tissues surrounding the ischemic core, 
and, the ischemic penumbra (del Zoppo and Milner, 2006).  Integrin expression 
following ischemia can be recapitulated in vitro using the oxygen-glucose deprivation 
(OGD) model. OGD limits the availability of oxygen and glucose needed for cell survival 
in vitro. Endothelial cells that have undergone OGD increase their expression of α5β1 
(Milner et al., 2008b), confirming this model is consistent with in vivo studies.  Other 
studies in adult mice have also observed an increase in α5β1 integrin expression using a 
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different hypoxic model, the hypobaric hypoxia model (Milner et al.). Taken together, 
these studies suggest that following ischemia there is an up-regulation in α5β1 integrin 
expression that induces the pro-angiogenic environment required for tissue repair and 
angiogenesis.  
Because I observed a pro-angiogenic effect induced by DV (Fig 2.2, 2.3 and 2.4), 
I reasoned that DV’s pro-angiogenic effect on brain endothelial cells might be because 
of both the absence of α2β1 and the presence of a distinct pro-angiogenic unidentified 
DV receptor. I decided to investigate whether DV’s pro-angiogenic effect is due to 
interacting with the α5β1 integrin. I chose this integrin because [1] perlecan, DV’s 
parent molecule, greatly increases α5β1 integrin expression in brain endothelial cells 
(Milner et al., 2008b), [2] perlecan supports β1 integrin mediated cell adhesion via its 
DV region (Brown et al., 1997) and [3] DV can inhibit cell adhesion to fibronectin 
(without directly binding to the fibronectin) (Mongiat et al., 2003), a primary ligand for 
α5β1.  
In this study I have demonstrated DV interacts with the α5β1 integrin and proven 
this integrin is required for DV’s pro-angiogenic effect in vitro. Our results demonstrate 
that DV co-localizes with the α5β1 integrin and binds to the α5β1 integrin with a Kd of 1.6 
x 10-7 ± 7.2 x 10-8 M.  DV also causes the up-regulation of α5β1 integrin mRNA 
expression. Lastly, DV is not capable of promoting angiogenesis in vitro when α5β1 
integrin is negatively modulated. These results suggest proteolytic fragments of DV in 
the ischemic environment present in the cerebral fluid are able to interact with newly 
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expressed α5β1 integrin subunits. The interaction of DV with the α5β1 integrin induces a 
pro-angiogenic effect and subsequently promotes brain self-repair.  
Materials and methods 
DV and α5 integrin binding assays 
Binding assays were carried out using an optical biosensor (IAsys; Affinity 
Sensors, UK) as described (Brittingham et al., 2005). In brief, to covalently bind the 
α5β1protein, designated as an acceptor, onto the surfaces of a sensor, carboxylate 
groups present on the surface were activated by injection of a 1:1 mixture of 0.1 M N-
hydroxysuccinimide and 0.4 M N-Ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(Pierce). The acceptor dissolved in phosphate buffered saline (PBS) was then allowed to 
bind to the activated surface until a response plateau was reached. The residual active 
groups were blocked by an injection of 100 µL of 1 M Tris-HCl (pH 8.5). 
A cuvette with immobilized α5 was primed with the binding buffer (150 mM 
NaCl, 25 mM Tris-HCl, pH=7.4, and 1 mM MnCl2) at 25°C for 10 min. A 100-µL sample 
containing free DV interactant dissolved in the binding buffer was added to the cuvette, 
and then the association phase was recorded. Subsequently, the sample was removed, 
analyte-free buffer was added to the cuvette, and the dissociation phase was recorded. 
After each assay, the surface of the cuvette was regenerated by a brief wash with 100 
mM glycine, pH=4, and followed by equilibration with the binding buffer. During 
regeneration cycles attention was paid to complete removal of the surface-bound 
74 
 
analyte, and the washing continued until a response equal to a baseline value was 
reached.  
For binding assays, free DV was added at concentrations ranging from 8.0 x 10-8 
M to 4.0 x 10-7 M. Data from the biosensor were analyzed by the global fitting method 
described by Myszka and Morton (Myszka and Morton, 1998). For each assay, the 
association rate constants (kon) and the dissociation rate constants (koff) were obtained, 
and the equilibrium dissociation constants (Kd) values were calculated from a ratio of 
koff/kon. In addition, control binding of bovine serum albumin (BSA) at the molar 
concentration of 8.0 x 10-7 (double of the highest concentration for DV) was also 
performed. 
Immunocytochemistry 
 Brain endothelial cells plated on type I collagen were treated with DV for 10 
minutes followed by fixation with 4% paraformaldehyde (VWR). α5β1 co-localization 
with administered DV was examined with antibodies directed to α5β1 (Millipore) and 
the 6X HIS tag on the human recombinant DV (Calbiochem). Appropriate secondary 
antibodies were used to stain for DV (Alexa fluor 488) and α5β1 (Alexa fluor 594) 
purchased from Invitrogen. 
α5β1 integrin knockdown 
Brain microvascular endothelial cells at 50% confluency were transferred from 
normal growth media to Optimem (Gibco) for 20 minutes.  Lipofectamine 2000 
(Invitrogen) and siRNA oligos targeted against the human α5 integrin (Mission siRNA; 
75 
 
Sigma) were diluted in Optimem media individually for 5 minutes.  Tubes were 
combined and incubated at room temperature for 20 minutes.  α5 SiRNA-containing 
media was then added to the brain endothelial cells dropwise and incubated for 2 
hours.  After 2 hours, Optimem was replaced with antibiotic free growth media (M199, 
10% FBS, 150 mg/ml bovine brain extract, 60 mg/ml heparin), and cells were allowed to 
recover overnight.  After 24 hours, the media was changed to normal growth media 
containing antibiotics. α5 integrin knockdown was confirmed by α5 QT-PCR and 
α5western blot. 
Proliferation assays 
Mouse  brain endothelial cells were seeded in 96-well plates at a concentration 
of 4 x 103 cells per well in IMDM media (Invitrogen) supplemented with 10% FBS 
(Invitrogen) 1x Antibiotic/Antimycotic and incubated overnight at 37C and 5% CO2. 
Following overnight incubation, complete media was aspirated off, and cells that 
underwent treatment were washed with plain IMDM media to remove residual serum. 
Purified DV and 1% media was added back to each well to a final volume of 100μL and 
incubated for an additional 24 hours at 37C and 5% CO2. After 24 hours, 20μL of MTS 
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium), was added to each well and incubated for an additional two hours at 37C 
and 5% CO2. Cell proliferation was measured following the two hour incubation by 
reading the 96-well plate at 490nm using plate reader. Proliferation was normalized to 
untreated 1% condition for each experiment.  
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Migration assay 
Cell migration was assessed with a modified Boyden Chamber (NeuroProbe, 
Gaithersburg, MD) following the instructions of the manufacturer. In the top chamber,  
brain endothelial cells were added to each well at a concentration of 50 x 103 cells per 
well. In the bottom chamber, VEGF (20ng/mL) or purified DV was added to each well. A 
polycarbonate membrane (PVD-free 8 micron pore) was coated with type I collagen 
and fitted in between the top and bottom chamber. After the chamber was set up, it 
was placed at 37C and 5% CO2 and incubated for 6-8 hours. Following incubation, the 
polycarbonate membrane was scraped on the apex surface to remove any cells that did 
not actively migrate through the 8 micron pores in the membrane. Next the membrane 
was incubated in 0.1% crystal violet for one hour, rinsed 3x with 1xPBS and cell number 
was counted using a microscope.  
Capillary tube-like formation assays  
24-well plates were incubated at -20C overnight along with 200μL pipette tips. 
Matrigel (VWR) was thawed on ice and approximately 50μL was aliquoted to each pre-
chilled well in the 24-well plate. Even coating of the matrigel was accomplished using a 
pre-chilled pasture pipette. During cell collection, the matrigel coated plate was placed 
at 37C and 5% CO2.  brain endothelial cells were seeded to each well at a concentration 
of approximately 50 x 103 cells per well in IMDM supplemented with 1% FBS to a final 
volume of 350μL. Purified DV was added to each well at a desired concentration. 
Experiments were run for 12-18 hrs at 37C and 5% Co2. Following incubation, cells were 
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fixed with 4% paraformaldehyde in 1x PBS. Tube formation was imaged and quantified 
as tube pixels/high power field, 10 areas per condition using Adobe Photoshop, CS.  
Results and discussion 
Angiogenesis following ischemia involves the degradation of the ECM, and an 
integrin “switch” to go from a quiescent environment to a pro-angiogenic environment. 
DV has been reported to regulate angiogenesis by interacting with the α2β1 integrin 
which is not present on microvascular brain endothelial cells. Data reported in the 
previous chapter suggest DV is inducing a pro-angiogenic effect on  brain endothelial 
cells. Therefore, I asked if DV could interact with a new integrin that is essential in 
promoting angiogenesis and re-expressed following ischemia. The α5β1 integrin is 
critical for vascular development (Francis et al., 2002) and promotes post-stroke brain 
angiogenesis (Milner et al.), but is otherwise down-regulated in the mature brain until 
re-expressed in brain endothelial cells after hypoxia (Milner et al.), (Milner et al., 
2008b).  Given my previous results and these observations, I reasoned that DV’s  
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pro-angiogenic effect could be because of interaction with the α5β1 integrin.  
DV co-localizes with and binds to the α5β1 integrin  
In order to investigate whether DV’s pro-angiogenic mechanism of action 
requires the α5β1 integrin I first set out to investigate whether DV co-localizes with the 
α5β1 integrin. Immunocytochemistry was incorporated to investigate the cell surface 
relationship between α5β1 and DV (Figure 3.1).  brain endothelial cells were treated in 
the presence or absence of DV (300nm) for 30 minutes and stained for α5β1 (green) and 
anti his-DV (red). In the control panel, cells not treated with DV show only surface 
staining of α5β1 and no staining of his-DV. α5β1 surface localization is spread out and 
uniform. In contrast to those results, cells treated with DV show staining of both α5β1 
integrin and DV, indicating the presence of DV.  Cells treated with DV demonstrate 
clustering of α5β1 integrin, a sign of integrin activation (Berrier, 2007) and co-
localization of DV and α5β1. To further demonstrate that DV’s interaction with  brain 
endothelial cells is mediated by the presence of the α5β1 integrin,  brain endothelial 
cells were subjected to α5β1 shRNA and assayed for staining of DV. As expected, there  
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Figure 3.1. DV co-localizes with α5β1 integrin.  brain endothelial cells were stained for 
α5β1 (red) and DV (anti-HIS, green) in order to investigate whether DV and α5β1 co-
localize. Top panel, Cells treated with DV (± DV treatment for 30 minutes) demonstrate 
DV and α5β1 integrin colocalization (yellow/orange color in merged field and as 
magnified in three boxes) and α5β1 clustering. Bottom panel,  brain endothelial cells 
with shRNA mediated knockdown of the α5β1 integrin show no detectable staining of 
DV which suggests the α5β1 integrin is required for DV’s interaction with  brain 
endothelial cells.   
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was no staining of α5β1 integrin in the cells treated with α5β1 shRNA (Figure3.1). shRNA 
cells treated with DV also showed no staining for DV, indicating the α5β1 is required for 
DV’s interaction with these brain endothelial cells. Collectively, these data suggest DV 
interacts with  brain endothelial cells by interacting with the α5β1 integrin. 
 To further investigate the molecular interaction between α5β1 and DV, I next 
incorporated optical biosensor analysis. The method is used to quantify the molecular 
interaction between two species by monitoring a change in mass without needing to 
label or modify the two molecular species being tested. The angle of extinction of light, 
reflected after polarized light impinges upon the film, is altered and monitored as a 
change in detector position for the dip in reflected intensity (Drescher, 2009). In my 
experimental model, soluble α5β1 integrin was immobilized to the cuvette and free DV 
was added at various concentrations (Figure 3.2). Under these conditions, DV was 
determined to bind the α5β1 integrin with a  kon, koff and Kd of 3.8 x 10
6 ± 2.7 x 105/M-s, 
7.2 x 10-1 ± 1.1 x 10-1/s and 1.6 x 10-7 ± 7.2 x 10-8 M, respectively.  BSA was run as a 
negative control and showed no binding to the α5β1 integrin, indicating DV binding to 
α5β1 integrin was specific.  
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Figure 3.2. DV binds α5β1 integrin. Optical biosensor traces showing the association 
and dissociation of DV and BSA (control) with immobilized α5 integrin. Concentrations 
of DV (determined by Bradford assay) and BSA used are listed in molarity on the right 
hand side. DV was determined to bind the α5β1 integrin with a  kon, koff and Kd of 3.8 x 
106 ± 2.7 x 105/M-s, 7.2 x 10-1 ± 1.1 x 10-1/s and 1.6 x 10-7 ± 7.2 x 10-8 M, respectively.  
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As the presence of integrin ligand is known to increase that integrin's 
intercellular expression (Milner et al., 2008b), and our data suggests DV is a ligand of 
α5, I next asked whether DV might also increase α5 integrin mRNA expression in  brain 
endothelial cells in vitro. Figure 3.3 demonstrates that by qPCR, after 1.5h or 3h of DV 
exposure, α5 mRNA expression increases by approximately 2 fold and 1.8 fold, 
*p=0.0001, and **p=0.006 respectively, as compared to cells not treated with DV. 
These results suggest DV increases mRNA expression of the α5 in brain endothelial cells.  
Collectively, these experiments demonstrate DV binds to, co-localizes with, and 
increases the mRNA expression of the α5β1 integrin.  
Negative modulation of α5β1 integrin abolishes DV’s pro-angiogenic effect 
 With the knowledge that DV co-localizes with and could directly bind to the α5β1 
integrin, I next set out to determine whether negatively modulating the α5β1 integrin 
would abolish DV’s pro-angiogenic effect on  brain endothelial cells. In order to 
negatively modulate the interaction of DV and α5β1 integrin, I incorporated two 
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Figure 3.3. DV increases α5 integrin mRNA expression in  brain endothelial cells. Fold 
change in mRNA of α5 integrin isolated from  cells treated ± DV for 1.5 hours and 3 
hours. Control mRNA levels were normalized to one and the natural log was then 
reported of this data. After 1.5 hours or 3h of DV exposure, α5 mRNA expression 
increases by approximately 2 fold and 1.8 fold, *p=0.0001, and **p=0.006 respectively, 
as compared to cells not treated with DV. (Error bars indicate standard error) 
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methods. The first method used short hairpin RNA constructs (shRNA) to knockdown α5 
integrin, the second method was using a soluble α5β1 integrin-GST and third method 
used synthetic peptides designed specifically for the binding pocket of α5β1. By 
inhibiting the α5β1 using these techniques, I was able to investigate the role α5β1 has in 
DV’s pro-angiogenic mechanism on  brain endothelial cells in vitro. 
 Gene silencing of α5 integrin was accomplished using shRNA. To confirm α5 
integrin was successfully knocked down, qPCR was performed to demonstrate a 
reduction in α5 integrin mRNA and western blot analysis was performed to confirm a 
reduction in protein level (Figure 3.4). Brain endothelial cells treated with lentiviral 
shRNA targeted towards α5 integrin showed a 75% reduction in both α5 integrin mRNA 
and α5 integrin protein level as compared to control.  Once α5 integrin was successfully 
knocked down in  brain endothelial cells, I then incorporated these cells in the 
previously used in vitro angiogenic assays: MTS proliferation assay and modified 
Boyden Chamber migration assay in order to investigate whether this integrin plays a 
role in DV’s pro-angiogenic effect in vitro. 
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Figure 3.4. Confirmation of α5 knockdown. Representative western blot and qPCR 
analysis of α5 integrin knockdown. Western blot (a) and (b) qPCR of wild type and α5 
shRNA treated  brain endothelial cells demonstrating a 75% knockdown of α5 protein, 
and mRNA, respectively (GAPDH loading control also shown). *p=0.0061.  
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Wild type  brain endothelial cells grown in IMDM supplemented with 1% FBS 
media were used as the baseline control population and their proliferation was 
arbitrarily set to 100%. α5 knockdown brain endothelial cells grown in IMDM  media 
supplemented with 1% FBS were treated incubated with or without DV [20 ug/mL] 
(Figure 3.5). α5 mediated knocked down  brain endothelial cells do not show significant 
inhibition of proliferation as compared to wild type  brain endothelial cells grown in 1% 
FBS supplemented media. This result suggests that, in reduced serum conditions, 
knockdown of α5β1 integrin has no effect on  brain endothelial cell proliferation. This 
result also implies shRNA mediated knockdown of α5β1 integrin was not toxic to brain 
endothelial cells because the MTS assay monitors both cell proliferation and cell death 
by monitoring cell metabolic activity. These results demonstrate DV significantly 
enhanced proliferation of wild type brain endothelial cells. Brain endothelial cells with 
α5 knocked down were no longer responsive to DV pro-proliferative effect. These 
results suggest DV’s pro-proliferative effects are because of the presence of the α5β1 
integrin on  brain endothelial cells, suggesting DV induces its pro-proliferative signal 
through the α5β1 integrin.  
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Figure 3.5. Blocking α5β1 inhibits DV’s effect on  brain endothelial cell proliferation.  
Quantification of proliferation of brain endothelial cells ± addition of the α5 integrin 
plasmid after 48 hours ± DV in serum free media as measured via MTS assay. Values 
shown (mean ± standard deviation normalized to control proliferation arbitrarily set to 
100%) demonstrate that α5 siRNA did not significantly inhibit brain endothelial cell 
proliferation (p=0.6), but did inhibit the positive (**p=0.002) proliferative effect of DV 
(##p=0.0001). 
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 Next, I asked if negative modulation of α5β1 integrin would inhibit DV’s pro-
migratory effect on  brain endothelial cells (Figure 3.6). In order to investigate this 
hypothesis, two separate experimental models were used. First, soluble α5β1-GST 
integrin was co-incubated with DV in the bottom wells of the modified Boyden 
chamber. This model was used to test the hypothesis that soluble DV co-incubated with 
soluble α5β1-GST integrin will block DV’s pro-migratory effect because of competition 
for binding of DV between soluble α5β1-GST and cell surface α5β1 integrin. As shown in 
Figure 3.6, endothelial cells migrating towards VEGF were used as a positive control. 
Interestingly, endothelial cells migrated towards DV suggesting DV is just as much of a 
chemoattractant as VEGF. Incubation of DV with soluble α5β1-GST blocked DV’s pro-
migratory response of  brain endothelial cells. To further demonstrate this integrin is 
required for DV’s effect on brain endothelial cell migration, brain endothelial cells with 
α5β1 knocked down were also treated with DV. Under this condition, DV was no longer 
able to promote migration of brain endothelial cells. Collectively, these data indicate 
the α5β1 integrin is required for DV’s pro-migratory effect on  brain endothelial cells.  
  
 
 
 Figure 3.6. Blocking α5β1 
mean number cells (± standard deviation) migrating towards 3% fetal bovine serum 
(control) or DV ± α5β1--GST or 
control (no chemotractant) demonstrating that DV was as powerful a chemo
3% serum which could be significantly inhibited by 
(**p=0.009)  
 
 
 
 
 
 
inhibits DV’s effect on brain EC migration. Quantification of 
α5 knockdown with α5 siRNA (as normalized to negative 
α5β1-GST (*p=0.02) or 
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tractant as 
α5 knockdown 
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Lastly, I determined if blocking the α5β1 integrin with the CRRETAWAC ligand, a 
ligand specific for a binding pocket in α5β1 integrin, would block DV’s effect on inducing 
tube-like structures and morphogenesis of human D3 cells. The CRRETAWAC ligand 
shares the same or overlapping binding site in α5β1 as RGD-containing peptides 
(Koivunen et al., 1994). Because the CRRETAWAC ligand is specific for the human α5β1 
integrin, I utilized the human D3 brain endothelial cell line to investigate DV’s effect on 
tube morphogenesis (Figure 3.7). Control D3 brain endothelial cells did not form tubes 
in the absence of DV. As expected, DV induced D3 brain endothelial cells to form tube 
like structures. This suggests DV’s effect is not species specific, as it has now been 
observed to have pro-angiogenic effects in murine and human brain endothelial cells. 
When D3 brain endothelial cells were pre-incubated with the CRRETAWAC ligand, DV‘s 
effect on promoting tube like structures was greatly inhibited. However, I did not 
observe complete inhibition of DV induced tube morphogenesis when co-incubated 
with the CRRETAWAC peptide. These data suggest DV may also share the same or 
overlapping binding site the CREETAWAC peptide has in α5β1, yet also suggests DV 
binds to other parts of the integrin that is substantial enough to promote some tube 
formation. Another explanation may be because of the fact that only one concentration 
for the peptide was used for this experiment. Future experiments would investigate if 
higher concentrations of the CREETAWAC peptide could completely block DV’s tube like 
formation. 
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Figure 3.7. Blocking α5β1 blocks DV’s pro-angiogenic effect on human D3 brain 
endothelial cell tube formation. Human D3 brain endothelial cells were treated ±DV 
300nm and ±DV CRRETAWAC peptide. DV induced D3 brain endothelial cells to make 
tube like structures and promote morphogenesis. In the presence of the α5β1 human 
specific blocking peptide, CRRETAWAC, DV’s capability to promote tube like structures 
and morphogenesis was inhibited.  
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In order to dissect the mechanism by which DV is promoting angiogenesis on 
brain endothelial cells in vitro, I first set out to identify a new receptor that is essential 
in promoting angiogenesis following ischemia in the brain. To date, little research has 
been performed linking integrins with angiogenesis in the post ischemic brain. Luckily, I 
did have some evidence to go on that led me to identify a new receptor responsible for 
DV’s pro-angiogenic effect on brain endothelial cells. First, in murine, rat and non-
human primates, angiogenic brain endothelia experience an integrin receptor switch 
after brain hypoxia from mature integrin receptors such as the α6β1, back to 
developmental integrin expression, α5β1, αVβ3, and β1, in order to promote 
angiogenesis (Lathia et al., 2009), (Milner and Campbell, 2002), (Milner et al., 2008a), 
(del Zoppo and Milner, 2006). Second, new evidence suggests that the αVβ3 integrin is 
non essential for post stroke angiogenesis, while the α5β1 integrin promotes brain 
endothelial cell proliferation following ischemia in a mouse model (Li, 2010). Third, 
perlecan, DV’s parent molecule, greatly increases α5β1 integrin expression in brain 
endothelial cells (Milner et al., 2008b), perlecan supports β1 integrin mediated cell 
adhesion via its DV region, (Brown et al., 1997) and DV can inhibit cell adhesion to 
fibronectin (without directly binding to the fibronectin) (Mongiat et al., 2003), a 
primary ligand for α5β1.  
Immunocytochemistry and Surface Plasmon resonance experiments suggest DV 
co-localizes with and binds to the α5β1 integrin with  a  kon, koff and Kd of 3.8 x 10
6 ± 2.7 x 
105/M-s, 7.2 x 10-1 ± 1.1 x 10-1/s and 1.6 x 10-7 ± 7.2 x 10-8 M, respectively. These data 
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would suggest that, following post stroke proteolysis of perlecan, DV is released into 
the vascular cerebral space. Following DV release, my data support the hypothesis that 
free DV is able to bind to the α5β1 integrin expressed on brain endothelial cells and 
promote brain angiogenesis. Moreover, my results also imply that DV could play a role 
in inducing the integrin receptor “switch” (Milner and Campbell, 2002) from a 
quiescent environment to a pro-angiogenic environment because DV increases mRNA 
expression of α5β1 integrin in brain endothelial cells. Other work performed in our 
laboratory supports the hypothesis that DV could play a role in inducing the integrin 
receptor “switch” because animals treated with DV following middle cerebral artery 
occlusion and resultant cerebral ischemia express significantly higher integrin levels of 
α5β1 in post-stroke brain tissue compared to contralateral tissue, (data not shown). 
Indeed, DV binds to α5β1 with a Kd of 160 nM which is weaker than its interaction with 
its previously reported receptor, α2β1 (Kd 80 nM) (Bix et al., 2004), yet these results 
could explain how DV induces its anti-angiogenic effect on  brain endothelial cells 
transfected with α2β1 plasmid. As DV’s affinity for each receptor is different, DV has a 
binding preference for α2β1. Therefore, if α2β1 integrin is expressed, the anti-angiogenic 
response will dominate.  
 Once I had identified α5β1 as a plausible receptor for DV on brain endothelial 
cells, I investigated whether this interaction was essential for modulating DV’s pro-
angiogenic effect. Therefore, DV’s pro-proliferative, migratory and tube like formation 
effect was blocked by negatively modulating the α5β1 integrin through shRNA mediated 
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knockdown, soluble α5β1-GST and CRRETAWAC peptide. From these experiments, I am 
able to conclude that DV requires the α5β1 integrin in order to induce its pro-angiogenic 
response on  brain endothelial cells.  
 Future experiments will investigate how DV interacts with the α5β1 integrin. 
Previous reports indicate DV interacts with α2β1 integrin via its I-domain (Bix et al., 
2004) yet the α5β1 integrin does not contain such domain (Diamond, 1994). My data 
with the CREETAWAC peptide may offer some clues as to where DV is binding to the 
α5β1 integrin since this peptide was able to inhibit DV’s effect on tube like formation 
and morphogenesis by brain endothelial cells. CRRETAWAC has been demonstrated to 
directly compete with Arg-Gly-Asp (RGD) containing peptides and mAb 16, which do 
not share the same binding sites (Mould et al., 1998). As DV does not contain an RGD 
binding motif and the CREETAWAC peptide blocks DV’s enhancement of tube formation 
one could suggest DV may share the same binding pocket as the CREETAWAC peptide 
on the α5β1 integrin.  Interestingly, opposite of what has been reported (Woodall et al., 
2008), my surface Plasmon resonance binding experiments had to be performed in the 
presence of Mn2+. These data suggest DV binding to the α5β1 integrin is cation-
dependent.  As bivalent cations have been shown to induce conformational relaxation 
that leads to exposure of ligand-binding sites in the α5β1 integrin (Mould, 1998), it is 
plausible that α5β1 must be “primed” in order for DV to bind to it.  
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CHAPTER IV 
PERLECAN DV INDUCES THE RELEASE OF VEGF FROM BRAIN ENDOTHELIAL CELLS VIA 
A MAP-KINASE DEPENDENT SIGNALING PATHWAY INVOLVING THE α5β1 INTEGRIN 
Introduction 
 Regulatory mechanisms involved in angiogenesis are essential for restoration of 
tissues in and out of the CNS. A better understanding of the mechanisms that inhibit 
angiogenesis would be beneficial for diseases such as cancer, whereas a better 
understanding of the mechanisms for promoting angiogenesis would be beneficial in 
cases such as limb ischemia or myocardial infarction (Navaratna, 2009). Studies 
performed by Krupkinski suggest that active angiogenesis following stroke is beneficial 
for the ischemic brain (Krupinski et al., 1993). Induction of angiogenesis in the CNS 
following ischemia would increase blood flow to affected tissues, reduce infarct size, 
promote neurogenesis and provide support for new neuronal networks (Navaratna, 
2009). Current evidence suggests active angiogenesis following ischemia occurs as soon 
as 12 to 24 hours in mice models and three to four days in humans (Navaratna, 2009). 
The discrepancy in time may have to do with when the samples are available to analyze 
in human models. However, how angiogenesis is induced following ischemia in the CNS 
remains to be answered.  
 Angiogenesis and neuroprotection following stroke involves the release and 
binding of growth factors such as epidermal growth factor, basic fibroblast growth 
factor, transforming growth factor beta and VEGF (Slevin, 2000) (Krupinski et al., 
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1994a). VEGF is a homodimeric protein that plays a critical role in angiogenesis during 
development, wound healing, cancer, cardiovascular diseases and ischemia (Zachary, 
2001). Five iso-forms of VEGF-A exist, differing in amino acids and affinity to their 
receptors.  The most abundant iso-form found in the brain, VEGF165, has been shown to 
regulate proliferation, migration and tube formation in endothelial cells (Kaji et al., 
2006), (Katsumata, 2010). VEGF expression is regulated at the transcriptional, 
translational and post transcriptional level. Secretion of VEGF following ischemia is 
related to activation of hypoxia-inducible factor pathways and intercellular signaling 
pathways. The majority, if not all VEGF, signaling is mediated by or involves VEGFR2 
(Zachary, 2001). Perlecan’s DV has previously been demonstrated to inhibit 
angiogenesis in HUVECs by negatively modulating VEGFR2, implicating a role for 
perlecan’s DV in growth factor downstream signaling (Nystrom et al., 2009).   
 VEGF is regulated at the transcriptional level by activating PI-3-K/AKT and MAPK 
signaling pathways (Hermann and Zechariah, 2009) and HIF-1α under normoxic and 
hypoxic conditions (Berra et al., 2000), (Levy, 1996) (Karni, 2002). The MAP kinase 
cascade is triggered by multiple extracellular molecules, is conserved from yeast to man 
and is involved in cell proliferation, cell differentiation and cell behavior (Pouyssegur, 
2002). Under normoxic conditions, mRNA levels of VEGF are rapidly induced by the 
p44/p42 MAP kinase cascade (Mazure, 2003).  Under normoxic conditions, ERK has 
been demonstrated to directly phosphorylate HIF-1α. This leads to increased levels of 
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the HIF-1α, and therefore HIF-1β and HIF-1α heterodimer complex, and activation of 
VEGF expression (Berra et al., 2000).  
It was not until recently, that investigators began to link ECM ligands with 
integrin binding for modulation of angiogenic growth factors. This becomes an 
interesting area of research for stroke because degradation of the ECM following 
ischemia produces bioactive fragments that are available to interact with cell surface 
receptors and subsequently regulate cell fate. ECM-specific ligands binding to the α5β1 
integrin have been linked to activating the ERK and PI 3-K cascades and promote retinal 
endothelial proliferation (Wilson, 2003). Research performed by Mousa et al. 
demonstrates that ECM fragments induce VEGF secretion by retinal pigmented 
epithelial cells, linking ECM degradation and promotion of angiogenesis.  
Perlecan’s C-most terminal fragment, LG3, is linked to activation of the ERK 
pathway (Soulez, 2010). Therefore, it would be logical to think perlecan’s DV could 
induce VEGF165 secretion by activating the ERK pathway. Yet, no work has been 
performed investigating this hypothesis. VEGF165 has also been linked to the induction 
of perlecan synthesis in brain endothelial cells (Kaji et al., 2006). Collectively, these data 
suggest a positive feedback loop where DV causes VEGF secretion and subsequent 
perlecan synthesis by activating the ERK signaling pathway. Therefore, because DV was 
promoting a pro-angiogenic effect on brain endothelial cells, and because VEGF is up-
regulated following ischemia, I investigated whether DV’s pro-angiogenic effect 
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involved VEGF up-regulation in brain endothelial cells. I later investigated if this effect 
involved the α5β1 integrin and activation of ERK and HIF-1α. 
I was first able to demonstrate that DV induces VEGF secretion by brain 
endothelial cells in a dose dependent manner due to DV up-regulation of VEGF mRNA 
levels. I later investigated the intercellular signaling cascades involved in DV up-
regulation of VEGF and demonstrated that DV activates AKT and ERK signaling cascades 
that lead to an increase in HIF-1α stabilization, thus increasing transcription of VEGF 
message. To investigate the significance of α5β1 integrin in DV’s pro-angiogenic effect, I 
utilized brain endothelial cells that were knocked down for the α5β1 integrin via shRNA 
and demonstrate these cells were no longer responsive to DV’s effect on VEGF’s mRNA 
levels or activation of AKT, ERK and HIF-1α. My results demonstrate that DV is pro-
angiogenic, and this effect involves DV signaling through the α5β1 integrin in order to 
activate AKT, and ERK signaling cascades that are responsible for increasing VEGF 
expression and secretion by stabilizing HIF-1α. VEGF165 induces perlecan synthesis in 
human brain endothelial cells and perlecan is the most sensitive ECM component 
following ischemia. Therefore my data suggests a positive feedback loop model by 
which fragments of perlecan, particularly DV, following proteolysis can replenish levels 
of perlecan inadvertently by causing the release of VEGF. 
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Materials and methods 
Construction of stable cells with α5β1 integrin knockdown 
Bacterial glycerol stocks with shRNA mediated clones to α5 integrin constructed 
within the lentivirus plasmid vector pLKO (Sigma) were streaked out onto agarose 
plates containing Ampicillin and grown overnight. Single colonies were picked and 
grown in 50mL LB-Amp media and grown overnight. Plasmid DNA was purified using 
Qiagen maxi prep kit. Recombinant lentiviral particle were made following purification 
of plasmid DNA. Plasmids were transfected into 293 EBNA cells using Lipofectamine™ 
2000 (Invitrogen) and Mission® Lentiviral Packaging Mix (Sigma) as per the supplier’s 
instructions. Once lentiviral particles were made, they were collected and lentiviral 
transduction was performed following lentiviral transduction protocol developed by 
Sigma Mission® RNAi team.  brain microvascular endothelial cells were grown to 70% 
confluency. Media was changed and fresh media with 20µL of Lentiviral particles were 
added to the appropriate wells. Plate was gently swirled and incubated an additional 18 
hours at 37C and 5% CO2. Following this incubation, media was removed and fresh 
media was added back to each well and incubated another 18 hours at 37C and 5% CO2. 
Next, the media was replaced with fresh puromycin (2.5µg/mL) containing media and 
incubated another 18 hours at 37C and 5% CO2. After this, media was replaced with 
fresh puromycin containing media every 3-4 days until resistant colonies were 
identified (five days). In order to confirm appropriate knockdown of α5 integrin 
knockdown in these cell lines, qPCR and western blot analysis was performed.  
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VEGF secretion ELISA analysis 
Confluent microvascular brain endothelial cells, and D3, were serum-starved for 
12 hours prior to experiments. Cells were washed with PBS, then fresh serum free 
media was added back to each well with desired concentrations of DV and incubated at 
37C and 5% CO2 for various time points up to nine hours. Following incubation, 
conditioned medium was collected and spun down at 10,000 X g for five minutes. After 
centrifugation, VEGF in the conditioned medium was detected following 
manufacturer’s instructions (RayBio® Mouse/Human VEGF-A ELISA Kit for serum, 
plasma and cell culture supernatant).  A standard curve was constructed and VEGF 
concentrations were plotted using SigmaPlot10.0. In some conditions, cells were 
pretreated the α5β1 integrin activating antibody SNAKA51 for 30 minutes prior to DV 
incubation (kindly provided by Martin Humphries) (Clark et al., 2005).  
Gene expression analysis using qPCR 
A 12 well plate of  cells was grown to confluency. Prior to the experiment, cells 
were serum starved overnight in 1% FBS IMDM media. The cells were then washed with 
PBS and fresh 1%IMDM +/-DV (20µg/mL) was added back to the wells and incubated at 
37C and 5% CO2 for various time points. At the end of the experiment, the media was 
aspirated, cells were rinsed with PBS, and the protocol from RNEASY MiniKit was 
followed. (Cat. #74104). Samples were quantified using a spectrophotometer and 
qualitative analysis was performed by running samples on a 1% agarose gel. First-strand 
101 
 
cDNA synthesis used cloned AMV RT for RT-PCR. cDNA from each sample was prepared 
following the Invitrogen cloned AMV Reverse Transcriptase protocol (Cat. No.12328-
019). Briefly, the following components were mixed in a RNASE-Free eppendorf tube: 
1uL oligo(dT)20 (500ug/mL), 1ug total RNA, 2uL 10mM dNTP Mix. Samples were 
incubated at 65C for 5 min collected by centrifugation and the following components 
were added: 4uL 5x cDNA Synthesis buffer, 1uL 0.1M DTT, 1uL Cloned AMV RT 
(15units/uL). The final volume was adjusted to 20uL and the samples were mixed and 
incubated at room temp for 10 min. The samples were then incubated at 45C for 1hr. 
The reaction was terminated by heating the samples at 85C for 5min. The samples were 
then adjusted to a final volume 200uL with RNA-FREE H2O. qPCR was performed using 
the following products: TaqMan® Fast Universal PCR Master Mix (2X), No AmpErase® 
UNG Cat. No. 4352042, MicroAmP® Fast 96-Well Reaction Plate, 0.1mL Cat. No. 
4346907 (AppliedBiosystems). Primer and probe sets designed for Vascular Endothelial 
Growth factor A. Assay ID Mm00437304_m1, Glyceraldehyde-3-phosphate 
dehydrogenase Assay ID Mm99999915_g1 and Integrin alpha-5. Assay ID 
Mm00439797_m1 were used. The following were mixed to a final volume of 25uL and 
added to TaqMan® Fast 96-well Reaction Plate: Fast Universal PCR Master Mix, gene 
expression assay mix, cDNA and H20. The amount of cDNA to add for each gene 
expression was optimized so that the dCT was around 18cycles. Once the reaction plate 
was complete, ∆CT and ∆∆CT values were calculated using Applied Biosystems 7500 
Fast Reverse transcriptase PCR software.  
102 
 
Cell signaling western immunoblot 
Confluent mouse brain microvascular endothelial cells or the same cells with 
shRNA mediated knockdown of α5β1 integrin were serum-starved for 24h prior their 
exposure to DV (20μg/mL). In experiments involving inhibitors, drugs were diluted in 
DMSO and incubated for 1hour at 37C and 5% CO2 prior DV addition. In all cases, the 
DMSO maximum concentration reached was not over 0.1%.  PI3Kinase, MEK1 and ERK 
inhibition experiments were performed by incubating cells in the presence of 10μM 
LY294002, 10μM U0126 or 10μM PD98059 (Cell Signaling Technology), respectively 1h 
prior to DV exposure. Cells were exposed to DV for 0, 5, 15 and 30 minutes. Following 
DV exposure, cells were washed with ice-cold PBS and homogenized in cell lysis buffer 
(Cell Signaling Technology) complemented with protease inhibitor cocktail (Calbiochem, 
EMD Chemicals, San Diego, CA). Accurate protein concentration was determined using 
BCA protein assay reagent (Thermo Scientific). 20 μg/lane of total protein from each 
sample were loaded in a 10% SDS-PAGE gel. Following electrophoresis (170 volts for 1 
hour) samples were transferred on PVDF membranes. Membranes were incubated in 
blocking buffer (5% BSA/ TBS) for 1h at room temperature followed by an overnight 
incubation at 4ºC in the presence of antibodies directed against phospho-Akt (1:1000, 
Cell Signaling), pan-Akt (1:1000, Cell Signaling), phospho-ERK1/2 (1:1000, rabbit, R&D 
Systems), pan-ERK1/2 (1:1000, R&D Systems), phospho-eIF4E (Cell Signaling), eIF4E 
(Cell Signaling), HIF-1α (1:500, Novus Biologicals) or glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH, 1:1000, Sigma-Aldrich). Membranes were washed with TBS-
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0.1% Tween 20 and incubated in presence of horseradish peroxidase (HRP) conjugated 
secondary antibody (GeneTex, Irvine, CA). Band detection was performed by enhanced 
chemiluminescent substrate (Picowest Signal, Thermo-Fisher Scientific) and captured 
by X-ray films. Blot quantification was performed using ImageJ software (ImageJ, NIH, 
Bethesda, MD).  
Statistical analysis 
Data are presented as Mean +/- standard deviation (unless otherwise stated). 
Statistical significance (p<0.05) was determined for all experiments by Student’s 
unpaired t-test with the Sigmastat software package.  
Results and discussion 
DV induces VEGF secretion in brain endothelial cells by increasing VEGF mRNA 
expression 
 In order to investigate how DV is promoting angiogenesis on brain endothelial 
cells, I investigated the possibility that DV regulates growth factors that are involved 
with angiogenesis following ischemia. I decided to determine if DV’s pro-angiogenic 
effect is due to the positive regulation of VEGF because [1] Hypoxia leads to a transient 
increase in expression of VEGF on several cell types, including endothelial cells, in the 
brains of both rats and mice (Ogunshola et al., 2000). [2] VEGF165 has been linked to 
induction of perlecan synthesis in human brain  
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microvascular endothelial cells (Kaji et al., 2006), suggesting a possible mechanism for 
how the brain replenishes the ECM following ischemia. [3] Interestingly, DV’s anti-
angiogenic effect is linked to the suppression of VEGF signaling in HUVEC due to the 
dephosphorylation of VEGFR2 (Nystrom et al., 2009). Therefore, I hypothesized that 
DV’s pro-angiogenic effect on brain endothelial cells involves VEGF165 (hereafter 
referred to as VEGF) stimulation. To the best of my knowledge, VEGF synthesis and 
release have not been previously linked to the activation of the α5β1 integrin.  
First I asked whether DV could increase levels of mRNA for VEGF and its 
receptor (VEGFR2) in brain endothelial cells in vitro using qPCR. Brain endothelial cells 
were treated with DV for 1.5 and 3 hours. VEGF mRNA levels were significantly 
increased at these time points, (8.2 fold and 2 fold, p=0.001 and p=0.003, respectively) 
and VEGFR2 mRNA levels (1.5 and 1.8 fold, p=0.002 and p=0.007, respectively) (Figure 
4.1). Earlier time points show no significant increase with DV treatment yet, later time 
points demonstrated that these levels go back to normal (data not shown). These 
results indicate that DV positively regulates both VEGF and VEGFR2 mRNA levels.  
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Figure 4.1. DV increases VEGF and VEGFR2 mRNA expression. qPCR from mouse brain 
endothelial cells ±DV treatment for 1.5 or 3 hours demonstrates a significant increase 
in VEGF mRNA (*p=0.001, **p=0.003) and VEGFR2 mRNA (#p=0.02, ##p=0.007) as 
compared to control (normalized to one and then shown in natural log scale).  
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To determine whether the increase in VEGF expression results in an increase in 
VEGF secretion, brain endothelial cells were treated with DV [20ug/mL] for 1.5 to 24 
hours, and the cultured media was analyzed for VEGF concentration using a VEGF ELISA 
kit. DV significantly increased VEGF secretion at all time points, and its effect peaked by 
nine hours, after which VEGF levels started to decline (Figure 4.2). My results also 
demonstrate that DV significantly increases VEGF secretion in a dose dependent 
fashion (Figure 4.3) over the course of nine hours. Collectively, these results 
demonstrate DV significantly increases VEGF protein secretion by brain endothelial 
cells. I next examined whether the VEGF secreted in the media by DV plays a role in 
DV’s in vitro pro-angiogenic effect. In order to investigate this hypothesis, I performed 
proliferation and matrigel tube-like formation experiments (previously described) using 
a VEGF neutralizing antibody. C75BL6 brain endothelial cells treated with the VEGF 
neutralizing function blocking antibody alone had no significant effects on proliferation 
or tube like formation. I was able to significantly block DV’s pro-proliferative effect 
using the VEGF neutralizing antibody (Figure 4.4). 
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Figure 4.2. DV causes a significant release of VEGF from brain endothelial cells. VEGF 
ELISA of conditioned media from  brain endothelial cells treated with DV [20ug/mL] at 
times indicated. N=3 for each time point measured. Values are mean ± standard 
deviation. DV caused a significant increase in measured VEGF levels at all time points 
measured (*p=0.01, **p=0.002, #p=0.006).  
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Figure 4.3. DV causes  brain endothelial cells to secrete VEGF in a dose dependent 
manner. VEGF ELISA of conditioned media from cells treated with DV at the times 
indicated. N=3 for each point. Values are mean ± standard deviation. DV causes a 
significant increase in measured VEGF levels at all time points measured indicating DV’s 
response is dose dependent (*p=0.04, **p=0.001, ***p=0.005, ****p=0.00004, 
фp=0.03, ффp=0.002, #p=0.003) Values are mean ± standard deviation.  
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However, brain endothelial cells treated with VEGF function blocker and DV had 
minimal effects on tube like formation compared to cell treated with DV alone (Figure 
4.5). These results suggest DV’s pro-angiogenic effect in vitro is only partly due to VEGF 
secretion induced by DV. Other possibilities that could be involved with DV’s pro-
angiogenic effect include DV’s ability to secrete other growth factors that are involved 
with regulating angiogenesis such as BDNF, FGF and EGF.  
Collectively, these results suggest DV can induce the secretion of VEGF by brain 
endothelial cells by increasing VEGF mRNA.  These results also imply that DV increases 
VEGFR2 protein levels because DV causes an increase in mRNA levels of VEGFR2. The 
ability of the VEGF neutralizing antibody to block DV’s pro-proliferative activity as well 
as mitigate its pro-tube-like formation effect, implies that the pro-angiogenic effect of 
DV is a two step mechanism. DV induces VEGF secretion, and newly secreted VEGF 
causes the pro-angiogenic response effect in vitro. Taken together, these results imply 
DV can promote a pro-angiogenic environment by increasing soluble growth factors 
and their receptors. My results also suggest a positive feedback loop mechanism by 
which the ECM is restored following injury. Fragments of perlecan are released and 
cause the secretion of VEGF. Newly secreted VEGF is able to bind to VEGFR2 and cause 
the subsequent synthesis of perlecan, where it can now be secreted into the ECM for 
restoration and remolding.  
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Figure 4.4. VEGF function blocking antibody inhibits DV’s pro-proliferative effect.  
brain endothelial cells were treated in the presence or absence of DV [20 ug/mL] ±VEGF 
[20 ug/mL] neutralizing antibody. These results indicate that DV’s pro-proliferative 
effect is due to DV’s induction of VEGF secretion.  
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Figure 4.5. VEGF function blocker retards DV’s effect on tube-like morphogenesis.  
brain endothelial cells were treated in the presence and absence of DV [20 ug/mL] ± 
VEGF [20 ug/mL] neutralizing antibody. DV promoted tube-like morphogenesis while 
VEGF neutralizing function blocking antibody retarded the DV effect.  
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The α5β1 integrin is involved with DV’s effect on VEGF expression and secretion 
 
 Having demonstrated that DV’s pro-angiogenic effects are α5β1 integrin and 
VEGF dependent, I next hypothesized DV’s effect on VEGF expression and secretion 
could be due to DV’s interaction with the α5β1 integrin. In order to test this hypothesis, 
I utilized the  brain endothelial cell α5β1 integrin knockdown cell line and the SNAKA-51 
antibody. The SNAKA-51 antibody was used to convert the α5β1 integrin into a ligand-
competent form. Because the maximal effect of VEGF expression was seen at three 
hours and DV’s most potent concentration observed thus far was 20 μg/mL,  brain 
endothelial deficient in α5β1 integrin were treated ± DV (20 μg/mL) for three hours, and 
VEGF expression was quantified. VEGF expression was not induced by DV in  brain 
endothelial cells with α5β1 integrin knockdown (Figure 4.6). This suggests that the 
interaction of DV and α5β1 integrin is necessary for DV’s induction of VEGF expression. 
In an experiment complementary to α5β1 integrin knockdown, I activated the α5β1 
integrin with the SNAKA-51 antibody, which activates α5β1 integrin by binding outside 
the ligand binding domain (Clark et al., 2005), and assayed VEGF secretion (Figure 4.7). 
Interestingly, activating the α5β1 integrin with the SNAKA-51 antibody significantly 
induced VEGF secretion by itself suggesting that activation of  α5β1 integrin can cause 
VEGF expression or some contamination in the media is causing VEGF secretion that is 
not significant when the integrin is not activated. Importantly, when SNAKA-51 
antibody was added in combination with DV, even more VEGF was secreted by  brain 
endothelial cells than by either addition alone, suggesting that activation of α5β1 
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integrin with SNAKA-51 enhances DV-induced VEGF secretion. These results also 
suggest most cells have the inactive form of this integrin and therefore, DV is slightly 
able to induce VEGF secretion because some active forms of this integrin exist due to 
cations present in the media. Yet when there is an abundance of activated integrin, DV 
is able to induce more VEGF secretion. DV could also be acting as an activator of the 
α5β1 integrin yet in this case I would expect to observed SNAKA-51 and DV to have 
similar effects on VEGF secretion. Suggesting DV probably activates this integrin and 
causes downstream signaling that is sufficient for VEGF secretion. Because VEGF 
release has also been tied to the αVβ3 integrin (Mousa et al., 1999), I investigated if this 
integrin played a role in DV’s effect on VEGF secretion. Human D3 brain endothelial 
cells were treated with DV ± αVβ3 integrin neutralizing antibody (1 µg/mL). This 
antibody was unable to inhibit DV-induced VEGF secretion suggesting that DV-induced 
VEGF release was unlikely the result from DV interacting with αVβ3 integrin (Figure 4.8). 
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Figure 4.6. DV interaction with the α5β1 integrin is crucial for DV’s effect on VEGF 
expression. WT  brain endothelial and α5β1 integrin null  brain endothelial cells were 
treated with DV (20ug/mL) for three hours. Knockdown of α5β1 integrin significantly 
blocks DV’s induction of VEGF mRNA expression as compared to WT  brain endothelial 
cells treated with DV. Untreated WT  brain endothelial cells were normalized to zero.  
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Figure 4.7. DV induced VEGF secretion is α5β1 integrin dependent. Brain endothelial 
cells treated with SNAKA-51 activating α5β1 integrin antibody [20 µg/mL] significantly 
increases VEGF secretion. Combination of SNAKA-51 activating α5β1 integrin antibody 
and DV [20 µg/mL] significantly increases DV’s induction of VEGF secretion as 
compared to DV alone. Brain endothelial cells with knockdown of α5β1 integrin are 
nonresponsive to DV treatment.  
 
  
 Figure 4.8. αVβ3 integrin does not 
brain endothelial cells were treated with DV (20 µg/mL) for three and nine hours. DV 
was able to significantly induce VEGF secretion from human D3 brain endothelial cells. 
Co-incubating αVβ3 function blocking antibody (1 μg/mL) with DV had no significant 
effect on DV’s induction of VEGF secretion. Control and 
have detectable amounts of VEGF in the media.
 
 
play a role in DV induced VEGF secretion.
αVβ3 function blocker did not 
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 Human D3 
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DV activates a novel signaling pathway to regulate VEGF expression 
 I next investigated whether several cell signal transduction components known 
to be involved in VEGF release might be activated by DV exposure and whether 
inhibition of these factors could inhibit DV-induced VEGF release. As Akt and ERK 
activation have been implicated in VEGF production and release (Berra et al., 2000), I 
determined whether DV could activate Akt and ERK in brain endothelial cells. Figure 4.9 
demonstrates that, as assayed by western blot, DV addition to brain microvascular 
endothelial cells results in AKT phosphorylation/activation. AKT phosphorylation 
remained elevated for at least 30 minutes (**p=0.02) as normalized to total Akt 
compared to controls.  Furthermore, this DV-induced Akt activation could be 
completely inhibited by the addition of the PI3K inhibitor LY-294002. Multiple 
concentrations of total protein lysate were run to demonstrate a significant difference 
between untreated and treated cells.  Next, I showed that DV phosphorylates/activates 
ERK in brain microvascular endothelial cells after 5 minutes (*p=0.001). ERK 
phosphorylation also remained elevated for at least 30 minutes (**p=0.02) as 
normalized to total ERK signal (Figure 4.10). This phosphorylation could be inhibited 
with the PI3K inhibitor LY-294002 (#p=0.003, ##p=0.009 as compared to DV changes). 
These data suggest DV activates AKT which then leads to the activation of ERK.  
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Figure 4.9. DV activates AKT by phosphorylation. DV phosphorylates/activates  brain 
endothelial cell Akt after 5 minutes (*p=0.005 versus control) and 30 minutes 
(**p=0.02 versus control) as demonstrated with representative western blot and plot 
(mean fold-change +/- standard deviation plotted) as normalized to total Akt signal. 
This activation is inhibited with LY294002. 
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Figure 4.10. DV causes phosphorylation of ERK. DV phosphorylates/activates ERK in 
brain microvascular endothelial cells after 5 minutes (*p=0.001, which persists to at 
least 30 minutes, **p=0.02) as demonstrated with representative western blot and plot 
as normalized to total ERK signal. This transient phosphorylation could be inhibited with 
the PI3K inhibitor LY-294002 (#p=0.003, ##p=0.009 as compared to DV changes). The 
inhibitor by itself had no significant effect on ERK phosphorylation. 
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Under both normoxic and hypoxic conditions (Karni, 2002), VEGF regulation has 
been linked to hypoxia-induced factor-1α (HIF-1α) activation. Under normoxic 
conditions, HIF-1α is constantly degraded and almost nonexistent, (Kaur, 2005) yet 
studies performed by Karni et al. demonstrate HIF-1α expression can also exist under 
normoxic conditions (Karni, 2002).  Therefore, I investigated whether DV treatment 
could causes changes in HIF-1α levels in brain endothelial cells (Figure 4.11). 
Application of 0.1% DMSO (vehicle) transiently stabilized HIF-1α which then rapidly 
became undetectable. Interestingly, DV induced rapid stabilization of HIF-1α which 
remained stable for up to 15 minutes, followed by a rapid decrease to barely 
detectable levels after 30 minutes. Because eukaryotic translation initiation factor 4E 
(elF4e) activation is linked to MAP kinase and PI-3 kinase signaling and activation of 
HIF-1α (Fukuda, 2002), the next logical factor to look at that is involved with HIF-1α 
expression was elF4e activation (Figure 4.12). HIF-1α stabilization correlated with 
increased phosphorylation of elF4E induced by DV. In addition, usage of U0126, a 
potent MEK inhibitor, reduced phosphorylation of elF4e, but did not have an effect on 
DV’s stabilization of HIF-1α.   
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Because DV mediates VEGF expression through the α5β1 integrin, I next 
investigated the activation of the same signaling molecules in my α5β1 integrin 
knockdown brain endothelial cells. Surprisingly, in α5β1 integrin knockdown brain 
endothelial cells (Figure 4.12) I observed constitutively HIF-1α stabilization. However, 
α5β1 integrin null brain endothelial cells in the presence of DV did not further 
significantly enhance HIF-1α levels suggesting that HIF-1α stabilization by DV is strictly 
regulated by α5β1 upstream signaling. Along the same lines as these results, α5β1 
integrin null brain endothelial cells had constitutively activated eIF4E (Figure 4.12). DV 
had no significant effect on phosphorylation of eIF4E in α5β1 integrin null brain 
endothelial cells. Phosphorylation of eIF4E in α5β1 integrin null brain endothelial cells 
was not blocked by U0126 inhibitor. This suggests a separate pathway besides MAP 
kinase involved with the phosphorylation of eIF4E.  Yet, because I did not see any 
significant changes in phosphorylation of eIF4E by DV in α5β1 integrin null brain 
endothelial cells plus U0126 inhibitor, my data suggests that α5β1 integrin is still 
required for DV’s phosphorylation of eIF4E and stabilization of HIF-1α.  
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Figure 4.11 DV increases accumulation of HIF-1α. DV treatment results in a sustained 
(from 5 to 30 min) increase of HIF-1α levels in  brain endothelial cells as demonstrated 
with representative western blot and plot (mean fold change as normalized to GAPDH 
loading control +/- standard deviation, *p=0.04, **p=0.01, ***p=0.001).  
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Figure 4.12 α5β1 integrin knockdown mediates DV activation of HIF-1α and eIF4E.  DV 
increases HIF-1α levels and phosphorylation/activation of e1F4E in an α5β1 integrin 
dependent fashion as demonstrated by representative western blots and respective 
plots (for HIF-1a, *p= 0.02, plotted as mean fold change +/- standard deviation) for 
e1F4E, **p=0.004, plotted a fold change in the ratio of phosphorylated e1F4E to total 
e1F4E. In both cases, DV-induced changes were absent in α5β1 knocked down cells and 
were blocked in wild type cells by the MEK inhibitor U0126. 
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I next investigated changes in phosphorylated Akt and ERK in α5β1 integrin null  
brain endothelial cells following exposure to DV and/or to U0126 (Figure 4.13) to 
investigate if DV activation of these molecules was dependent upon the presence of 
this integrin. As previously observed, DV treatment significantly increased both 
phospho-Akt (Figure 4.13) and phospho-ERK (Figure 4.13) in wild-type cells. Whereas 
U0126 treatment significantly affected DV-induced ERK phosphorylation, I observed a 
slight decrease in phospho-Akt levels. Interestingly, α5β1 integrin null  brain endothelial 
cells, displayed significantly high levels of phospho-Akt whereas phospho-ERK levels 
were significantly low compared to wild-type in control conditions. In contrast to wild-
type cells, DV did not significantly increase phosphorylation of AKT or ERK in α5β1 
integrin null  brain endothelial cells. U0126 significantly blocked ERK phosphorylation in 
α5β1 integrin null  brain endothelial cells without affecting phospho-AKT levels 
suggesting that HIF-1α stabilization in knockdown cells may be controlled by Akt, rather 
than ERK.  
Finally, ERK signaling pathway inhibition by U0126 (Figure 4.14) significantly 
blocked DV-induced VEGF mRNA levels as well as VEGF secretion (Figure 4.15). 
Collectively, these studies demonstrated the ability of DV to independently activate Akt 
and ERK in mouse brain endothelial cells. This results in HIF-1α stabilization through a 
elF4E dependent mechanism and ultimately leads to the secretion of VEGF.  
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Figure 4.13. α5β1 integrin suppression decreases phospho-ERK levels and increases 
phospho-Akt levels. (a) Representative Western-blot of phospho-Akt and phospho-ERK 
levels in wild-type and α5-knockdown cells. Cells were treated without or with 20μg/mL 
of DV and/or 10μM U0126 (MEK inhibitor). Pan-Akt and ERK were used to quantify 
changes in phosphorylation levels, GAPDH was used as an internal loading control. (b) 
Akt phosphorylation (pAkt) is induced by DV in wild-type cells, not in knockdown cells. 
Note the significant increase in pAkt levels compared to baseline (*p=0.078) in wild-
type, whereas α5-knockdown showed constitutive high pAkt levels under basal 
conditions (#p=0.0344). (c) ERK phosphorylation is up-regulated by DV and down-
regulated in α5-knockdown cells. Note the significant increase (*p=0.0336) following DV 
treatment. Treatment with U0126 abolishes DV-induced ERK phosphorylation (pERK). 
Surprisingly, α5-knockdown cells showed hypophosphorylated pERK levels (
#p=0.0002). 
DV was not able to increase pERK levels in knockdown cells. 
 
 
 Figure 4.14.Blockade of ERK by inhibition blocks DV’s positive effect on VEGF mRNA 
expression. Inhibition of ERK with U0126 inhi
microvascular endothelial cells (*p=0.02) which could not be prevented with the 
addition of DV (**p=0.05). Mean values +/
 
 
bits VEGF mRNA production in brain 
- standard deviation shown. 
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Figure 4.15. ERK inhibitor U0126 significantly blocks DV’s effect on VEGF secretion. 
Inhibition of ERK with U0126 inhibitor significantly blocks DV’s effect on VEGF secretion 
at three (*p=0.01) and six hour incubation (**p=0.04). Mean values +/- standard 
deviation shown. 
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VEGF has been implicated in regulating vascular remodeling in post-ischemic 
neurovascular coupling (Hermann and Zechariah, 2009). Five separate iso-forms of 
VEGF-A exist, differing in the number of amino acids and affinity to their receptors.  The 
most abundant iso-form found in the brain, VEGF165 (investigated in this dissertation), 
has been shown to regulate proliferation, migration and tube formation in endothelial 
cells (Kaji et al., 2006), (Katsumata, 2010). This iso-form, along with VEGF121, are more 
diffusible variants allowing these two VEGF forms to act over long distances compared 
to VEGF189 and VEGF206, which are matrix bound and can only provide short distance 
guidance clues (Kaji et al., 2006). Current evidence suggests extracellular matrix 
proteolysis, i.e. the generation of matrix fragments such as DV, induces VEGF following 
ischemia (Hermann and Zechariah, 2009). Interestingly, VEGF has emerged as a 
"double-edged sword" in stroke research. If given too soon after the onset of stroke, it 
promotes a leaky blood brain barrier, edema, hemorrhagic transformation and can 
ultimately worsened brain injury (Zhang et al., 2000). However, when administered 
later and more chronically, such as 24 hours post-stroke, VEGF it is  pro-angiogenic, 
neuroprotective, and enhances neurogenesis (Sun et al., 2010) (Ferrara, 2003). 
Therefore the timing of when VEGF is administered or released is critical in the overall 
outcome of brain repair.   
Current evidence linking VEGF secretion to ECM components is limited, 
especially in brain endothelial cells following ischemia. The work performed by Zong-
Mei et al and Mousa et al does provide some evidence that ECM components can 
129 
 
induce the secretion of VEGF in retinal pigmented endothelial cells.  Zong-Mei et al 
have discovered that thrombin is able to induce VEGF secretion in retinal epithelial cells 
(Zong-Mei, 2007). Research performed by Mousa et al demonstrate VEGF induced 
secretion,  using retinal pigmented endothelial cells, is differentially affected by 
normoxia, hypoxia, ECM components and integrins α5β1 and  αvβ3 (Mousa et al., 1999) . 
Indeed, as mentioned earlier, there is matrix proteolysis and up-regulation of VEGF 
following ischemia that happens simultaneously, yet no research has been performed 
to determine what role matrix fragments, such as DV, play in the brain following 
ischemia.  
My results indicate that DV can significantly and dose-dependently increase the 
secretion of VEGF by brain microvascular endothelial cells in vitro. This up-regulation of 
VEGF secretion induced by DV is correlated to an increase in mRNA expression of the 
VEGF gene. DV significantly increases VEGF mRNA as early as 1.5 hours and tapers off 
after six hours with DV treatment. It was not until VEGF was significantly upregulated at 
the mRNA level, 1.5 hours, until I began to observe a significant increase in VEGF that 
was secreted into the media. Suggesting DV is not effecting protein stability within the 
cell yet instead affecting protein production. Soluble VEGF secreted into the media 
accumulated for nine hours before degradation of VEGF was detected at 24hrs. An 
explanation for this observation is the biological half-life of VEGF. The biological half-life 
of “free” VEGF165 is 90 minutes, and VEGF release from collagen plateaus after 12 hours 
and no longer detectable following 24 hours (Kleinheinz, 2010). As my mRNA data are 
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only “freeze frames” in time, it would be interesting to see how long VEGF is actually 
expressed in cells treated with DV and if there is a correlation of VEGF expression and 
DV presence. In order to do such an experiment, one could incorporate luciferase-
based assays to monitor VEGF expression in real time and soluble DV by means of 
western blot.  
Due to my observations that DV increases VEGF secretion into the media and DV 
promotes endothelial cell proliferation and tube like morphogenesis, I next investigated 
if DV’s pro-angiogenic effect was due to the subsequent secretion of VEGF. In order to 
investigate the correlation of these phenomena, proliferation and tube like 
morphogenesis were assayed with DV in the presence of VEGF neutralizing antibody. 
These experiments suggest when VEGF is neutralized, DV’s effect on promoting  brain 
endothelial cell proliferation is significantly reduced and  brain endothelial cell tube like 
morphogenesis is inhibited as well. Collectively, these data suggest DV’s pro-angiogenic 
effect is due to the secretion of VEGF.  
To the best of my knowledge, my discovery of a direct association between α5β1 
ligand binding and VEGF release in brain endothelial cells has not previously been 
shown. Specifically, I have demonstrated that α5β1 integrin is essential for DV-induced 
VEGF mRNA expression via shRNA knockdown of α5β1 integrin. In the absence of the 
α5β1 integrin, DV no longer induces a significant increase in VEGF mRNA. Additionally, 
the α5β1specific activating antibody SNAKA-51 results in increased VEGF release and 
profoundly augmented DV-induced VEGF release (Clark et al., 2005). These results 
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suggest that activation of α5β1 integrin leads to a more pronounced effect of DV and 
possible synergism between activating α5β1 integrin and DV for VEGF release. 
Collectively with shRNA and activation of α5β1 integrin, I have demonstrated this 
integrin is important in DV’s effect on VEGF expression and secretion. Mousa et al have 
previously demonstrated that the addition of the α5β1 integrin ligand fibronectin to 
retinal pigmented epithelial cells could increase their secretion of VEGF, but this 
response was only partially inhibited with function blocking α5β1 antibody suggesting 
that other, non- α5β1 dependent mechanisms were involved (Mousa et al., 1999). 
Whether this link between α5β1 integrin and VEGF release is an additional 
distinguishing characteristic of brain endothelial cells versus other endothelial cells 
remains to be proven. To investigate if other integrins such as the αVβ3 integrin could be 
related to VEGF modulation by DV, blockade of αVβ3 integrin was performed. αVβ3 
integrin blocking experiments, with function blocking antibody and soluble αVβ3 integrin 
demonstrated that this integrin is not significantly involved with DV’s induction of 
VEGF. This further underscores that DV’s effect on VEGF induction is α5β1 mediated.  
Subsequent to ischemia a “pro-angiogenic environment” is reported partly due 
to the re-expression of developmental receptors (Milner et al., 2008a), (Milner and 
Campbell, 2002), (Milner et al., 2008b). As breakdown of the ECM is a vital step in 
promoting angiogenesis following ischemia in the brain, I next investigated if treatment 
of brain endothelial cells with soluble DV could increase pro-angiogenic receptors such 
as the α5β1 integrin and VEGFR2. This data would give insight as to whether DV plays a 
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role in promoting the pro-angiogenic switch following ischemia. Interestingly, DV up-
regulated α5β1 integrin and VEGFR2 mRNA expression in  brain endothelial cells. Other 
experiments in our laboratory also confirmed that DV increases α5β1 integrin expression 
in vivo in mice and rats subject to hypoxia (data not shown). The actual mechanisms by 
which DV increases α5β1 integrin and VEGFR2 mRNA expression remains to be proven, 
yet these preliminary experiments suggest DV plays a significant role in not only 
promoting angiogenesis by increasing migration, proliferation and tube formation of 
brain endothelial cells, but also by increasing pro-angiogenic receptors on brain 
endothelial cells allowing other pro-angiogenic factors to bind and promote 
angiogenesis.  
In this study, I demonstrated that DV activated both ERK and Akt signaling 
pathways in brain endothelial cells, in agreement with the literature (Alghisi and Ruegg, 
2006). Erythropoietin, a growth factor that stimulates blood vessel formation, has also 
been suggested to increase secretion of VEGF by activating PI3K/AKT and ERK pathways 
(Hermann and Zechariah, 2009). DV has been previously shown to activate FAK, 
p38MAPK and HSP27 but not ERK in HUVECs (Bix et al., 2004). The activation of those 
signaling molecules via binding of DV to  integrin led to an anti-angiogenic effect 
and actin disassembly. Because I observed the opposite effect, i.e. a pro-angiogenic 
effect subsequent to AKT and ERK activation in  brain endothelial cells where  
integrin is absent, our results support the concept that DV anti-angiogenic effects do 
not occur in the absence of the α2β1 integrin (Woodall et al., 2008).  
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I found that DV induced a rapid activation of both the ERK and Akt signaling 
pathways following a similar time course with a maximal phosphorylation at 5 minutes 
followed by a progressive decrease after 30 minutes. Such findings agree with a recent 
study by Chetty and colleagues (Chetty et al., 2009) who demonstrated that activation 
of αvβ3-induced VEGF secretion in lung carcinoma occurred through a PI3K/Akt 
dependent mechanism. However I observed that ERK signaling pathways dominated 
over the PI3K/Akt pathway to up-regulate VEGF expression as both PD98059 and 
U0126 (MEK inhibitors) could completely inhibit DV-induced VEGF secretion from brain 
endothelial cells.  
Following these observations, I further investigated the possible molecular 
mechanisms by which DV-induced ERK activation could result in VEGF secretion. 
Hypoxia-induced factor-1α (HIF-1α) constitutes one of the major signaling pathways 
known to up-regulate VEGF (Forsythe et al., 1996). Although HIF-1α stabilization 
following hypoxic conditions (when O2 availability is diminished) is well known and 
considered to be its main regulatory pathway, recent studies have suggested evidence 
that HIF-1 stabilization may also occur by certain oxygen-independent pathways such 
as the mammalian-target of rapamycin (mTOR) signaling pathway or downstream of 
PI3K/Akt signaling pathway (Hudson et al., 2002) (Zhong et al., 2000).  
As PI3K inhibition was not sufficient to efficiently suppress DV-induced VEGF 
transcription and secretion (data not shown), I suggest that subsequent HIF-1α 
stabilization by activation of the PI3K/Akt/mTOR axis remains marginal compared to 
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the ERK signaling pathway. Interestingly eukaryotic initiation factor 4E (elF4E), a major 
protein involved in protein translation, constitutes a merging point for both ERK and 
Akt signaling pathways, as well as an upstream signal for oxygen-independent HIF-1α 
stabilization (Ye et al., 2010) (Berra, 2000) (Karni, 2002) (Jin, 2008). In my study, I 
demonstrated that DV significantly increased both ERK and eIF4E phosphorylation. 
Inhibition of DV-increased phosphorylation was only achieved by the presence of MEK 
inhibitors or by α5-integrin silencing. 
 Although the mechanism by which α5-integrin down-regulates HIF-1α under 
normoxic conditions remains unclear, a recent study from Ryu and colleagues (Ryu et 
al., 2010) demonstrated that HIF-1α induced both α5-integrin and fibronectin 
expression in squamous cell carcinoma. Preliminary data obtained with my α5-
knockdown cells shows hyper-phosphorylated Akt levels under basal condition, 
whereas ERK appeared hypo-phosphorylated compared to wild-type. Such data raises 
the speculation that ERK and Akt may be differentially implicated in HIF-1α 
stabilization. Whereas ERK-induced HIF-1α stabilization in wild-type cells requires the 
presence of both DV and α5β1 integrin receptor, HIF-1α stabilization in α5 knockdown 
cells appears to be both ERK and DV-α5β1 integrin dependent and suggests exclusive 
involvement of the PI3K/Akt signaling pathway via mTOR signaling. In addition, such 
results also suggest the presence of two different feedback loops by α5-integrin 
towards Akt and ERK: a positive feedback loop towards the ERK pathway, further 
elicited by DV binding, and a negative feedback loop towards PI3K/Akt that can be 
135 
 
partially (DV-induced Akt phosphorylation) or completely waived (α5-knockdown). To 
the best of my knowledge, such a feedback loop has not previously been 
demonstrated. Therefore, further investigation is required to better discern whether 
HIF-1α inhibition by α5-integrin relies on oxygen-dependent (prolyl-hydroxylases) or 
independent (e.g. mTOR, elF4E) pathways. Such studies will definitively shed new light 
on HIF-1α regulation by integrin signaling pathways. 
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CHAPTER V 
CONCLUSIONS AND FUTURE DIRECTIONS 
In my dissertation work, I set out to investigate the mechanistic role of 
perlecan’s DV fragment in brain endothelial cells by 1) investigating the in vitro 
angiogenic effects of perlecan’s DV fragment on brain cerebral endothelial cells 2) 
identifying whether the α5β1 integrin, present in brain endothelial cells and critical for 
brain angiogenesis, could be a novel DV pro-angiogenic receptor and 3) determining 
the regulation of VEGF by DV in brain endothelial cells as a model for understanding the 
mechanism of DV mediated angiogenesis.  
In Chapters I and II, I investigated the in vitro angiogenic effect DV had on brain 
endothelial cells in vitro and tied this effect to a new, unidentified receptor for DV, the 
α5β1 integrin. A problem that occurs when interpreting in vitro angiogenic assay data is 
incorrectly classifying a molecule as anti/pro-angiogenic (Auerbach, 1991) (Auerbach et 
al., 2000) (Auerbach et al., 2003). This normally occurs when the molecule is tested in 
only one model for angiogenesis. As mentioned previously, angiogenesis occurs in 
several steps and therefore, the more models an angiogenic agent is tested in, the 
more convincing this agent is for regulating angiogenesis. In order to investigate in vitro 
the stages involved with angiogenesis, I incorporated three different in vitro angiogenic 
techniques: modified Boyden Chamber, matrigel and MTS assays to monitor brain 
endothelial migration, tube like morphogenesis and proliferation respectively. 
Problems that arise using in vitro techniques because of propagation in vitro include 
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differences in activated state, loss and gain of attributes found in vivo such as cell 
surface antigens, receptor activation and modification of karyotypes. To avoid these 
problems I ensured cells that were used still expressed cellular markers such as von 
willebrand factor, VE-Cadherin and CD31/PECAM by western blot and 
immunocytochemistry. I also incorporated multiple cell lines, ranging from human (Vu, 
2009) to mouse (Sapatino et al., 1993), in order to confirm my results were not due to 
artifacts from a certain cell line. One of the key criteria for investigating an angiogenic 
response in vitro is confirming it  with in vivo  experiments (Jain, 1997). Our laboratory 
utilizes the mouse model because of its close genetic homology to humans and because 
mice are better tools for investigating physiological systems, such as the nervous, that 
mammals share. However, there are significant physiological, neuroanatomical and 
metabolic obstacles between humans and rodents we must overcome in order to 
translate bench to bedside results (Braeuninger, 2009). 
In contrast to its anti-angiogenic effect on HUVECs (Bix et al., 2004), DV 
significantly enhanced migration, proliferation and tube like morphogenesis in brain 
endothelial cells in vitro, suggesting DV was interacting with a new, pro-angiogenic 
receptor. The α5β1 integrin has been proven to be necessary for angiogenesis and up-
regulated following ischemia (Milner et al., 2008a) (Li et al., 2010), and has been 
previously indicated to be influenced by perlecan, although the specific domain of 
perlecan involved with this process remains unknown (Mongiat et al., 2003) (Milner et 
al., 2008b). Therefore, to maintain consistence with in vivo and in vitro observations, I 
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narrowed my search down to the α5β1 pro-angiogenic receptor and confirmed this 
receptor was responsible for DV’s pro-angiogenic effects. In order to investigate 
whether DV’s pro-angiogenic mechanism of action required the α5β1 integrin, two 
methodologies were incorporated, immunocytochemistry and optical biosensor 
analysis. Using these two separate methodologies, I was able to demonstrate 1) the 
α5β1 integrin is required for DV’s interaction with brain endothelial cells and 2) DV binds 
to the α5β1 integrin with a Kd of 160 nM.  Indeed, most other endothelial cells express 
both the α2β1 and α5β1 integrin, begging the question of why DV is anti-angiogenic in 
these co-expressing cells. The answer most likely lies in DV's varying affinity for each 
receptor. As stated above, Bix et al (Bix et al., 2004), using the same techniques as I did 
in this dissertation, have previously demonstrated that DV binds to α2β1 with a Kd of 80 
nM, exactly twice as strong of an interaction as that between α5β1 and DV. Therefore, 
in the presence of both receptors, DV will have a binding preference for the α2β1 
integrin and because of this preference the anti-angiogenic response will predominate. 
I was able to support this hypothesis by making brain endothelial cells express the α2β1 
integrin, (Figure 2.2) which resulted in DV inhibiting rather than enhancing their 
proliferation. 
The presence of integrin ligand is also known to increase that integrin's 
intracellular expression (Milner et al., 2008b). Because my data suggested DV was a 
ligand for α5β1 integrin, I next investigated whether DV might also increase α5 integrin 
mRNA expression in mouse brain endothelial cells in vitro. DV significantly increased 
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mRNA expression of α5 in mouse brain endothelial cells which further suggested DV is a 
plausible ligand for the α5β1 integrin.  
 After identifying α5β1 integrin as a new receptor for DV, I next investigated if the 
interaction between α5β1-DV was responsible for DV’s pro-angiogenic effect. In order to 
answer this question, I revisited the previous in vitro angiogenic assays performed in 
Chapter I and negatively modulated the α5β1 integrin by either shRNA mediated 
knockdown, soluble α5β1-GST or a CREETAWAC peptide specific for the binding pocket 
in the α5β1 integrin. My results demonstrated that brain endothelial cells subjected to 
α5β1 integrin shRNA mediated knockdown no longer showed an increase in proliferation 
when treated with DV.  To ensure these results were not because of the effects of 
shRNA transduction and RNAi activation, a non-targeting control was shown to have no 
effect. Indeed, the α5β1 integrin can cause proliferation in endothelial cells. Therefore, 
the absence of this integrin may negatively influence endothelial cell proliferation. But 
cells with α5β1 knocked down showed no significant difference in proliferation 
compared to wild type brain endothelial cells. Therefore, I was able to conclude that 
the induction of DV’s pro proliferative effect is due to the presence of the α5β1 integrin.  
In order to link this receptor to DV’s pro-migratory effect, I conducted 
competition studies with the α5β1 integrin. DV incubated with soluble α5β1 integrin no 
longer promoted endothelial cell migration. This suggests that when co-incubated, DV 
and soluble α5β1 integrin interact with one another thereby preventing soluble DV from 
binding to α5β1 on the cell surface and inducing its pro-migratory effect on brain 
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endothelial cells. One could argue that in this case, there is no more DV available to 
induce a pro-migratory effect with other plausible receptors. Yet, brain endothelial cells 
with α5β1 integrin knocked down were unresponsive to DV as a migratory stimulus. This 
result further supports the hypothesis that the α5β1 integrin is involved with DV’s pro-
migratory effect. Lastly, brain endothelial cells pre-treated with the CRRETAWAC 
peptide, a peptide specific for the binding pocket of α5β1 integrin (Mould et al., 1998), 
demonstrated an inhibitory effect on DV’s pro-tube-like morphogenesis.  
These results also provide insight into how ECM proteolysis following ischemia 
is beneficial for brain repair by providing bioactive ligands responsible for inducing 
angiogenesis. As mentioned previously, fibronectin is up regulated following ischemia 
and interacts with the α5β1 integrin (Milner et al., 2008a). Fibronectin also has been 
demonstrated to promote brain endothelial cell survival and proliferation through the 
α5β1 integrin by activating the MAP kinase signaling pathway (Wang and Milner, 2006a). 
These results suggest DV and fibronectin share similar characteristics when promoting 
angiogenesis in brain endothelial cells. Yet, there still exist differences between DV and 
fibronectin in regards to binding to the α5β1 integrin. DV and fibronectin have different 
affinities for the α5β1 integrin, Kd of 160nM and Kd of 1.5nM, respectively. Fibronectin 
also utilizes the RGD binding domain in the α5β1 integrin binding pocket. My results 
utilizing the CREETAWAC peptide suggests the α5β1 integrin has multiple binding sites 
for DV. The exact interaction as to how DV binds to the α5β1 integrin is left to be 
determined.  
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Collectively, these results demonstrated DV has an unexpected, opposite role 
on brain endothelial cells involving a newly identified receptor for DV. These data 
suggest following ischemia, DV is released into the cerebral vasculature and promotes 
angiogenesis by interacting specifically with newly expressed α5β1 integrin on brain 
endothelial cells. Indeed, other cells within the neurovascular unit, for example 
neurons and astrocytes, express DV’s previously reported receptor, the α2β1 integrin. 
Yet preliminary studies in our laboratory suggest DV has no negative effects on these 
cell types, suggesting DV has multiple roles in brain repair following ischemia. 
Based upon my observations that DV and fibronectin share the same receptor, I 
used fibronectin as a model to gain insight in to how DV could induce a pro-angiogenic 
response. Fibronectin promotes proliferation of brain endothelial cells by interacting 
with the α5β1 integrin and activating the MAP kinase signaling cascade (Wang and 
Milner, 2006a). Therefore, I investigated if the MAP kinase and upstream activator AKT 
were activated by DV. DV addition to brain microvascular endothelial cells resulted in 
AKT phosphorylation/activation which could be completely inhibited by the addition of 
the PI3K inhibitor LY-294002, demonstrating DV is activating P I3 kinase in order to 
activate AKT. My results also demonstrated DV phosphorylates/activates ERK in brain 
endothelial cells. This was AKT dependent, because the PI3K inhibitor LY-294002 
blocked the phosphorylation of ERK indicating DV signals through AKT in order to lead 
to the activation of ERK.  
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Under both normoxic and hypoxic conditions (Karni, 2002), VEGF regulation has 
been linked to hypoxia-induced factor-1α (HIF-1α) activation, therefore, I next set out 
to determine whether DV treatment could cause changes in HIF-1α levels in brain 
endothelial cells. Typically under normoxic conditions, HIF-1α is constantly degraded 
and present at very low concentrations (Kaur, 2005). Yet, studies performed by Karni et 
al. demonstrate that HIF-1α expression can also exist under normoxic conditions when 
HIF-1α synthesis is faster than its  degradation (Karni, 2002). My results demonstrated 
DV induced rapid stabilization of HIF-1α which was linked to phosphorylation of 
eukaryotic translation initiation factor 4E (elF4e), a downstream activator of MAP 
kinase and PI-3 kinase signaling (Fukuda, 2002). In addition, usage of U0126, a potent 
MEK inhibitor, reduced phosphorylation of elF4e, but did not have an effect on DV’s 
stabilization of HIF-1α suggesting that although DV causes an increase in ERK 
phosphorylation and eIF4E, other signaling cascades must be involved with DV’s 
stabilization of HIF-1α which are yet to be determined.   
As Akt and ERK activation have been implicated in VEGF production and release, 
(Berra et al., 2000) and VEGF causes the synthesis of perlecan in brain endothelial cells, 
I next set out to investigate whether DV regulated VEGF expression and secretion. From 
my results, I was able to conclude DV increased VEGF mRNA levels and increased VEGF 
secretion in a dose-dependent and time-dependent fashion in vitro. After observing 
that DV induced an up-regulation in transcription and subsequent release of VEGF into 
the media, I set out to determine if this effect was modulated by the α5β1 integrin. To 
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the best of my knowledge, the only integrins expressed following ischemia that have 
been linked to VEGF secretion are the α5β1 and αVβ3 integrins (Choi, 2009) (Mousa et 
al., 1999).  Utilizing the α5β1 integrin knockdown cells that I constructed, I determined 
that DV no longer had an effect on increasing VEGF expression and secretion, 
demonstrating this integrin is required for DV-mediated regulation of VEGF. 
 I followed this experiment up by asking if activating the α5β1 integrin could 
increase DV’s effect on VEGF secretion by utilizing the SNAKA-51 antibody (Clark et al., 
2005). The proposed mechanism of action induced by the SNAKA-51 antibody is that it 
causes the legs of the integrin to change conformation and thereby primes the integrin 
to bind to the ligand. Interestingly, cells treated with SNAKA-51 antibody alone 
significantly induced the secretion of VEGF into cultured media compared to non-
treated cells. This observation suggests a ligand present in the media that would 
typically not induce VEGF secretion is able to do so once the α5β1integrin has been 
primed for binding. Alternatively, this implies that activation alone of the α5β1integrin 
can cause VEGF secretion, an observation that has not been published as of yet. If this 
were the case, then changes in intercellular signaling molecules would provide insight 
to support or deny this hypothesis. This data coincides with DV’s previous effect on 
platelet activation where differences in integrin activation/ligand affinity state 
mitigated DV’s effect [Bix 2007]. These data also suggest the majority of this integrin on 
the cell surface is primarily in a bent conformation state. Suggesting that activating the 
α5β1 integrin provides a synergistic effect with DV treatment by putting the integrin in a 
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ligand competent form. Future studies would investigate intercellular signaling 
cascades in the presence or absence of SNAKA-51 antibody and also investigate if 
SNAKA-51 co-incubated with DV would make DV’s effect more prominent.  When cells 
were treated with DV and SNAKA-51, there was a significant increase in VEGF secretion, 
more than DV treatments and with SNAKA-51 alone. 
As mentioned previously, the αVβ3 integrin has also been linked to VEGF 
secretion. Therefore, I next set out to rule out that this integrin played a role in DV’s 
effect on VEGF secretion. In order to do this, I incorporated two separate scenarios. The 
first scenario was blocking the αVβ3 integrin with a function blocking antibody and 
incubating brain endothelial cells with DV. Under this scenario, DV still significantly 
induced VEGF secretion in the presence of αVβ3 function blocking antibody and this 
effect was not significantly different from DV treated alone. To further rule out that the 
αVβ3 integrin is not involved with DV’s induction of VEGF secretion, DV was co-
incubated with soluble αVβ3. Under this scenario, I hypothesized that if DV bound to 
soluble αVβ3, DV would no longer be able to bind to αvβ3 on the cell surface and induce 
VEGF secretion. My results indicated that DV was still able to induce VEGF secretion 
when co-incubated with soluble αVβ3, suggesting DV does not bind to this integrin. In 
order to support the hypothesis that DV does not bind to the αVβ3 integrin, I performed 
solid phase ELISA binding experiments and demonstrated DV did not bind to αVβ3 
integrin.  
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Collectively, these experiments confirm DV’s effect on VEGF expression and 
secretion involves the α5β1 integrin and this effect does not involve the αVβ3 integrin.  It 
is important to note that Mousa et al also demonstrated that the addition of 
fibronectin, the main ligand for the α5β1 integrin, to retinal pigmented epithelial cells 
could increase their secretion of VEGF. However, this response could not be inhibited 
with function blocking α5β1 antibody, suggesting that other, non α5β1 dependent 
mechanisms were involved with VEGF secretion (Mousa et al., 1999).   
Because my results suggested that the DV mediated increase in VEGF expression 
was α5β1 dependent, I next investigated the activation of the same signaling molecules 
in α5β1 integrin knocked down brain endothelial cells. Interestingly, α5β1 integrin 
knocked down mouse brain endothelial cells displayed significantly high levels of 
phospho-Akt, whereas phospho-ERK levels were significantly low compared to wild-
type in control conditions. In contrast to wild-type cells, DV did not significantly 
increase phosphorylation of AKT or ERK in α5β1 integrin knocked down mouse brain 
endothelial cells, showing DV requires this integrin cause phosphorylation of these 
molecules. I also observed a constitutive stabilization of HIF-1α and eIF4E. However, DV 
did not further significantly increase HIF-1α levels or phosphorylation of eIF4E. 
Although I observed constitutive activation of Hif1α and eIF4E, VEGF expression and 
secretion were not significantly increased in α5β1 integrin knockdown brain endothelial 
cells. These data suggest the downstream signaling cascade responsible for VEGF 
secretion via the α5β1 integrin does not entirely consist of HIF-1α stabilization and 
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phosphorylation of eIF4E. Because I observed a decrease in phosphorylation of ERK in 
these knocked down cells and because the U0126 ERK inhibitor blocked DV’s effect on 
VEGF expression and secretion, I was able to conclude DV primarily signals through the 
MAPK signaling pathway to induce VEGF production. My data also suggests that when 
the MAPK signaling pathway is blocked, other signaling molecules are activated in order 
to compensate and still allow DV to induce some of its pro-angiogenic effect.  
Whether this link between α5β1 integrin and VEGF release is an additional 
distinguishing characteristic of brain endothelial cells versus other endothelial cells 
remains to be proven. Given these results, as VEGF regulates perlecan synthesis in brain 
endothelial cells (Kaji et al., 2006), it is tempting to speculate that DV induced VEGF 
release from brain endothelial cells could result in a positive feedback loop that results 
in increased perlecan synthesis, which in turn restores the levels of perlecan deposits 
within the ECM following ischemia. 
Relative importance and future implications 
 Understanding the mechanisms involved with regulating angiogenesis can be 
beneficial for clinical applications in numerous fields such as ischemia, coronary 
vascular disease, wound healing and tumorigenesis. As ischemic stroke is the leading 
cause of long term disability and the third leading cause of death in the United States, a 
better understanding of brain repair following ischemic stroke can significantly increase 
the recovery of patients who have suffered from ischemic stroke. The data presented in 
my dissertation provides yet another avenue of therapy for ischemia with the novelty 
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of using bioactive fragments that are native to the brain following a post-ischemic 
response. The use of matrix fragments has already been incorporated in studies for 
inhibiting angiogenesis in cases such as cancer, macular degeneration and diabetic 
retinopathy (Hamano and Kalluri, 2005; O'Reilly et al., 1997) (Bix et al., 2006). The 
benefits to using angiogenesis inhibitors derived from circulation and/or the ECM 
include decreased toxicity effects and a lower risk for drug resistance, making these 
inhibitors great candidates for therapeutic approaches (Folkman, 2004). Another 
benefit to incorporating bioactive fragments derived from the ECM involves the ability 
to modify these proteins in order to increase their half-life or stability thereby 
decreasing dose requirements (Meng-jie, 2009). The notion of using native fragments 
produced by the brain following ischemia instead of drugs may also seem to be 
beneficial as they may not experience much resistance crossing the blood brain barrier 
as most pharmacological studies still struggle with overcoming. Also, drugs are artificial 
substances to the body and therefore subject to all of the problems associated with 
such foreign substances including side effects, tolerability, toxicities, etc. 
Little research has been spent investigating whether matrix fragments can 
promote angiogenesis for cases such as brain ischemia. It is plausible that the reason 
for this is an assumption that anti-angiogenic molecules will be anti-angiogenic in the 
brain. In addition to my results, there are several circumstances in which this is not the 
case. For example, endostatin promotes angiogenesis in immature endothelial cells 
derived from differentiated embryonic stem cells (Schmidt et al., 2004) and platelet-
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derived pro-angiogenic sphingosine-1-phosphate (S1P) is anti-angiogenic in brain 
endothelial cells due to their lack of MT1-MMP expression (Pilorget et al., 2005). An 
explanation for these different responses may be due to endothelial heterogeneity, 
whereby endothelial cells in different vascular beds, in this case brain versus non-brain, 
respond differently to angiogenic factors. Differential responses may also be due to 
differences in respective microenvironments, differences in expressed receptors, such 
as the presence or absence of α2β1 integrin, or differences in signal transduction 
components.  
A number of animal studies within the past few years have demonstrated that 
improving neuroprotection or post-stroke angiogenesis/neurogenesis can improve 
stroke outcome. Current stroke therapies generally fit into three different categories; 
pharmacological agents, growth factors and stem cell therapies. In particular, 
therapeutics that induce angiogenesis following ischemia have proven to be a 
promising area of research for future clinical stroke therapy as it promotes both blood 
flow and nutrients back to dying tissue along with promoting neurogenesis (Fan, 2007).  
Currently, there are only four molecules, VEGF, basic fibroblast growth factor 
(bFGF), granulocyte-colony stimulating factor (G-CSF) and Epo which have made it to 
pre-clinical trial for functional recovery in humans (Matthias, 2009). Pro-angiogenic 
therapy for stroke using VEGF has emerged as a “double-edged sword” in stroke 
research. Deng et al. have shown that 24 hours post-rat MCA stroke administration of 
bone marrow-derived mesenchymal stem cells resulted in improved neurological 
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function, reduced neuronal apoptosis and the promotion of neuronal proliferation via 
the release of VEGF (Deng et al., 2010). These results suggest VEGF is also 
neuroprotective. Yet, if VEGF is given too soon after the onset of stroke, it promotes a 
leaky blood brain barrier, edema, hemorrhagic transformation and an ultimately 
worsened brain injury (Zhang et al., 2000). However, when administered later and 
more chronically, such as 24 hours post-stroke, VEGF is  pro-angiogenic, 
neuroprotective, and enhances neurogenesis (Sun et al., 2010) (Ferrara, 2003). 
Therefore the timing in which VEGF is administered is detrimental for obtaining positive 
results. 
For the first time ever, my results link VEGF expression and secretion from brain 
endothelial cells to an ECM fragment. My results demonstrated DV causes an increase 
in VEGF secretion in brain endothelial cells, suggesting besides being pro-angiogenic, 
DV can also potentially be neuroprotective by causing the secretion of VEGF. Current 
experiments in our laboratory performed by Dr. Lee have investigated the administered 
effects of DV in vivo. After one day post stroke, DV administration did not cause an 
increase in permeability, suggesting DV at this time point does not induce negative 
permeability effects caused by VEGF. Yet, future studies should investigate the exact 
timing when DV administration causes VEGF production in vivo. Future experiments 
should also investigate the differences between VEGF expression and secretion in 
perlecan-hypomorph animals and wild type animals. Because perlecan null animals lead 
to embryonic lethality, preliminary studies utilizing perlecan-hypomorph animals would 
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allow us to investigate whether the presence of perlecan affects VEGF expression 
following ischemia.  
The mechanism by which VEGF is neuroprotective requires the VEGFR2 
(Matthias, 2009). Preliminary data using a VEGF neutralizing antibody suggest DV 
directly causes the increase in expression of VEGFR2. It is interesting to note that in 
HUVECs, DV causes a de-phosphorylation in VEGFR2 by activation of SHP-1 (Nystrom et 
al., 2009). Therefore investigating the mechanism by which DV causes an increase in 
VEGFR2 expression may also prove to be beneficial in understanding the complexity of 
DV’s direct and indirect pro-angiogenic effect.  Nonetheless, my data demonstrates 
that DV increases VEGFR2 expression in vitro, indicating DV could potentially promote 
neuroprotection two-fold by inducing the secretion of VEGF and by increasing the 
expression VEGFR2. The latter scenario would be beneficial for VEGF that is already 
present in the environment.  
DV increased VEGF secretion by activating the α5β1 integrin. Linking VEGF 
secretion with α5β1 integrin activation has never been shown thus far and therefore 
provides yet another pathway for the brain to promote angiogenesis following 
ischemia. Nine integrins have been reported to be expressed on endothelial cells 
(Laurens, 2009). Of those nine, there are three integrin receptors involved with 
angiogenesis in the brain that could be potential targets for promoting angiogenesis 
following ischemic stroke: α5β1, αvβ5 and αvβ3 (del Zoppo and Milner, 2006). To the best 
of my knowledge, only the α5β1 and αVβ3 integrins have been linked to VEGF secretion 
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(Choi, 2009) (Mousa et al., 1999). Yet the role of αvβ3 integrin in ischemic cerebral 
angiogenesis appears to be complex. Li and co-workers recently demonstrated that 
although the αvβ3 integrin is strongly induced on angiogenic brain endothelial cells in 
mice subject to hypoxia, β3 integrin null mice demonstrate no obvious defects in 
cerebral angiogenesis following hypoxia. Furthermore, β3 null mice following hypoxia 
exhibited an up-regulation in α5 integrin and an increase in proliferating cerebral 
endothelial cells (Li, 2010), suggesting the αvβ3 integrin is not detrimental for 
promoting angiogenesis following ischemia. My results also support the hypothesis that 
the αvβ3 integrin is not involved with the up-regulation of VEGF. Collectively, our data 
further demonstrates that the αvβ3 integrin plays a minimal role in supporting 
angiogenesis and neuroprotection following ischemia by having no effect on growth 
VEGF secretion.   
In vivo experiments performed by Dr. Lee in our laboratory confirm 
administration of DV enhances both neuroprotection and angiogenesis in rodents 
following ischemia resulting in normalization of stroke affected motor function. Dr. 
Lee’s experiments also supported my findings in vivo by demonstrating DV increases 
post stroke α5β1 integrin levels and correlated this finding with increased 
neuroprotection and angiogenesis in the brain. Therefore, developing therapies that 
can promote angiogenesis by signaling through this integrin and/or induce the 
expression of this integrin would hypothetically induce a pro-angiogenic environment 
and promote brain repair. Anti-angiogenic agents targeting integrins have been 
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exploited for therapeutic application in gliomas, melanoma, and prostate cancer 
(Idbaih, 2008) (Silva, 2008). However, few investigations have been performed to 
address targeting integrins for promoting angiogenesis in cases such as brain ischemia. 
As mentioned previously, there is an angiogenic “switch” following hypoxia that 
involves the up-regulation of α5β1 integrin. My results with the SNAKA-51 antibody, 
demonstrate activating the α5β1 integrin promotes VEGF secretion. Furthermore, my 
results also demonstrate DV promotes angiogenesis by signaling through the α5β1 and 
DV up-regulates the expression of this integrin. Collectively, my results demonstrate 
targeting the α5β1 integrin following ischemia could be exploited for therapeutic 
application to help promote angiogenesis and neurogenesis through its involvement 
with inducing VEGF production.  
Collectively my results, along with Dr. Lee’s results, demonstrate extracellular 
matrix components generated following ischemia can lead to potential neuroprotective 
and angiogenic therapeutic agents for patients who suffer from ischemia. Yet our 
results are only the beginning in describing DV’s role in brain angiogenesis and 
neuroprotection following ischemia. For starters, DV contains two Leu-Arg-Glu (LRE) 
tripeptides within its sequence (Murdoch et al., 1992). LRE tripeptides are binding 
ligands for neurons and control neurite outgrowth and migration (Hunter et al., 1991). 
Therefore, in the case of nerve injury such as ischemia or spinal cord injury, it would be 
interesting to investigate DV’s role in regulating neurite outgrowth and if these 
tripeptide sequences within DV serve as a recognition signal for neuronal migration. 
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The data presented in this dissertation suggests DV has a positive effect on endothelial 
migration. An explanation for this effect could be because of DV binding to α-
dystroglycan (Whitelock, 2008) a receptor responsible for linking the ECM to intracellular 
actin. The association between perlecan and dystroglycan has been investigated and 
provides yet another role for perlecan in controlling cell polarity (Lindner, 2007) 
(Mirouse, 2009). Yet, in order to investigate the above explanations for DV’s effect on 
neuronal and endothelial migration, site directed mutagenesis targeting the LRE 
tripeptides and knockdown of dystroglycan would be the first steps I would perform to 
investigate their role in DV’s effect on cell migration. 
As mentioned previously, perlecan is the most sensitive vascular matrix 
component following ischemia (del Zoppo et al., 2007). In my dissertation I only 
discussed proteases that could potentially cleave DV from full length perlecan. Other 
proteases exist such as thrombin, plasmin, collagenase, and stromelysin, which can 
release other fragments from perlecan besides DV. Thrombin activity is elevated 
following MCAO (Hua, 2003). Perlecan is sensitive to proteolysis by thrombin at four 
separate sites along its sequence. Proteolysis of perlecan could be beneficial as 
perlecan’s domain I contains multiple glycosaminoglycan (GAG) attachment sites, 
responsible for sequestering growth factors, and thrombin can cleave domain I from 
perlecan. Therefore, when thrombin levels are elevated growth factors, such as VEGF 
189, once anchored to the vascular basement membrane by perlecan’s GAG chains are 
now released and able to interact with the surrounding vascular environment.  
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In summary, I have successfully identified a new role for perlecan’s DV fragment 
following brain ischemia. My research has opened up a new field in brain recovery 
following stroke by linking ECM degradation and the promotion of angiogenesis. These 
results open up new avenues for understanding the mechanisms involved with brain 
self-repair following ischemia. One could hypothesize the following working model 
illustrated in Figure 5.1 that occurs following ischemia: DV is released from perlecan 
due to up-regulation of proteases after ischemia and this free DV interacts with 
different cell surface receptors such as the α5β1 integrin. Interaction with the α5β1 
integrin leads to phosphorylation of MAPK and HIF-1 stabilization and the subsequent 
induction of VEGF expression and secretion. Newly secreted VEGF is now capable of 
affecting the surrounding neurovascular unit where it can modulate angiogenesis 
during brain repair and promote synthesis of perlecan. 
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Figure 5.1. DV mechanism for inducing a pro-angiogenic and neuroprotective effect. 
DV is released from perlecan due to up-regulation of proteases and this free DV is 
capable of interacting with a different receptor the α5β1 integrin. Interaction with the 
α5β1 integrin leads to phosphorylation of MAPK and HIF-1 stabilization and the 
subsequent induction of VEGF expression. VEGF is now capable of affecting the 
surrounding neurovascular unit where it can modulate angiogenesis during brain 
repair. 
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